The Effects of vanilloid-like agents on platelet aggregation by Almaghrabi, SY
 
	
	
	
	
THE EFFECTS OF VANILLOID-LIKE 
AGENTS ON                           
PLATELET AGGREGATION 
 
 
Safa Yousef Almaghrabi, MBBS  
School of Human Life Sciences 
 
 
 
 
 
Submitted in fulfilment of the requirements for the degree of  
Master of Biomedical Science (Research)  
 University of Tasmania 
October 2012 
 
 
	 i
DECLARATION  
I hereby declare that this thesis entitled The Effects of Vanilloid-Like Agents on 
Platelet Aggregation contains no material which has been accepted for a degree or 
diploma by the University or any other institution, except by way of background 
information and duly acknowledged in the thesis, and to the my knowledge and 
belief no material previously published or written by another person except where 
due reference is made in the text of thesis, nor does the thesis contain any material 
that infringes copyright.  
Date: 24th Oct 2012 Signed:  
 
AUTHORITY OF ACCESS 
This thesis may be made available for loan and limited copying and communication 
in accordance with the Copyright Act 1968. 
Date: 24th Oct 2012 Signed:  
 
STATEMENT OF ETHICAL CONDUCT 
The research associated with this thesis abides by the international and Australian 
codes on human and animal experimentation, the guidelines by the Australian 
Government’s Office of Gene Technology Regulator and the rulings of the Safety, 
Ethics and Institutional Biosafety Committees of the University. 
Date: 24th Oct 2012 Signed:   
 
 
 
Full Name: Safa Yousef O. Almaghrabi 
 
	 ii
ACKNOWLEDGEMENTS 
First of all, I would like to thank the Government of Saudi Arabia (King Abdulaziz 
University) for the scholarship and sponsorship. 
 
I would also like to sincerely acknowledge my supervisors, Dr. Murray Adams, 
A/Prof. Dominic Geraghty, and Dr. Kiran Ahuja for their guidance, tolerance and 
being there whenever needed. 
 
I will not forget Merrilyn Johnson for her great help in the haematology laboratory 
and special thanks to the volunteers who donated with their precious blood and time. 
 
At last but not the least, I would like to thank my husband, Abdul, for his 
understanding, love and full support throughout these years. Many thanks as well to 
my parents for their continuous moral support.    
 
 
 
 
	
	
	
 
	  
	 iii
Table of Contents 
DECLARATION i 
ACKNOWLEDGEMENTS ii 
Table of Contents iii 
List of Figures vi 
List of Tables viii 
List of Abbreviations ix 
Abstract xii 
Chapter 1 LITERATURE REVIEW 1 
1.1 Introduction 2 
1.2 Haemostasis 3 
1.2.1 Platelets 3 
1.2.1.1 Platelet Structure and Function 3 
1.2.1.2 Platelet Activation 5 
1.2.1.3 Platelet Receptors 9 
1.2.2 Blood Coagulation 14 
1.2.2.1 Tissue Factor Pathway 14 
1.2.2.2 Natural Inhibitors of Blood Coagulation 16 
1.2.3 Fibrinolysis 17 
1.3 Cannabinoid Receptors 18 
1.3.1 Endogenous Cannabinoids (Endocannabinoids) 19 
1.4 Transient Receptor Potential Vanilloid Channels 20 
1.4.1 TRPV1 Structure 21 
1.4.2 TRPV1 Function 22 
1.4.3 TRPV1 Distribution 26 
	 iv
1.4.4 Biochemical Pharmacology of TRPV1 27 
1.5 Vanilloids 28 
1.5.1 Endogenous Vanilloids 29 
1.5.2 Plant Derived Vanilloids 29 
1.5.2.1 Plant-Derived Vanilloid Targets and Actions 31 
1.5.2.2 Clinical Applications of Plant-Derived Vanilloids 32 
1.5.2.3 Plant-Derived Vanilloid Toxicity 38 
1.6 Project Aims 39 
Chapter 2 Materials and Methods 40 
2.1 Ethics 41 
2.2 Materials 41 
2.2.1 Preparation of Platelet Aggregation Agonists 42 
2.2.2 Preparation of Vanilloids 42 
2.3 Methods 42 
2.3.1 Platelet Aggregation 42 
2.3.2 Lactate Dehydrogenase (LDH) Cytotoxicity Assay 45 
2.3.3 Measurement of Alpha Granule Release 45 
2.3.4 Statistical Analysis 46 
Chapter 3 Results 47 
3.1 Effect of Vanilloid-Like Agents on ADP-Induced Aggregation 48 
3.2 Effect of Vanilloid-Like Agents on Collagen-Induced Aggregation 53 
3.3 Effect of Vanilloid-Like Agents on Arachidonic Acid-Induced Aggregation 57 
3.4 Effect of SB-452533 on ADP-induced Platelet Aggregation 65 
3.5 Cytotoxicity Assay 65 
3.6 Effect of Vanilloids on Alpha Granule Release 67 
	 v
Chapter 4 Discussion 69 
BIBLIOGRAPHY 79 
APPENDICES 109 
Appendix 1: Manual of PF4 ELISA Kit 109 
Appendix 2: Manual of β-TG ELISA Kit 116 
Appendix 3: Manual of LDH Cytotoxicity Assay 123 
 
	  
	 vi
List of Figures 
Figure 1-1 ADP and Platelet Activation .................................................................... 13	
Figure 1-2 Schematic Diagram of the Coagulation Cascade ..................................... 15	
Figure 1-3 Chemical Structures of Endogenous Cannabinoids ................................. 20	
Figure 1-4 Regions and Amino Acids involved in TRPV1 Function ........................ 21	
Figure 1-5 Chemical Structures of the Capsaicinoids ................................................ 31	
Figure 3-1 Effect of CAP (A), DHC (B), NADA (C) and OLDA (D) on ADP-
induced Aggregation .......................................................................................... 49	
Figure 3-2 Effect of Plant-Derived Vanilloids on ADP-induced Platelet Aggregation
 ............................................................................................................................ 51	
Figure 3-3 Effect of Endovanilloids on ADP-induced Platelet Aggregation ............. 52	
Figure 3-4 Effect of NADA (A) and OLDA (B) on Collagen-induced Aggregation 53	
Figure 3-5 Effects of Plant-Derived Vanilloids on Collagen-induced Platelet 
Aggregation ........................................................................................................ 55	
Figure 3-6 Effects of Endovanilloids on Collagen-induced Platelet Aggregation ..... 56	
Figure 3-7 Effect of Vanilloids on the Lag-Time of Collagen-induced Platelet 
Aggregation ........................................................................................................ 57	
Figure 3-8 Effect of Capsaicin (A), DHC (B) and NADA (C) on Arachidonic Acid-
induced Aggregation .......................................................................................... 58	
Figure 3-9 Effects of Plant-Derived Vanilloids on Arachidonic Acid-induced Platelet 
Aggregation ........................................................................................................ 60	
Figure 3-10 Effects of Endovanilloids on Arachidonic Acid-induced Platelet 
Aggregation ........................................................................................................ 61	
Figure 3-11 Effect of Vanilloids on the Lag-Time of Arachidonic Acid-induced 
Platelet Aggregation ........................................................................................... 62	
	 vii
Figure 3-12 Effects of SB-452533 on Capsaicin- and OLDA-mediated inhibition of 
Platelet Aggregation induced by ADP ............................................................... 66	
Figure 3-13 Effects of Vanilloids on Platelet Alpha Granule Release....................... 68	
 
 
	  
	 viii
List of Tables 
Table 1-1 Contents of Platelet Granules ...................................................................... 4	
Table 1-2 Platelet Alpha Granule Contents and Functions .......................................... 6	
Table 1-3 Major Sub Endothelial Matrix Constituents that support Platelet Adhesion
 .............................................................................................................................. 7	
Table 1-4 Platelet Receptors for Adhesive Protein .................................................... 10	
Table 1-5 Platelet Integrins ........................................................................................ 10	
Table 3-1 Effect of Vanilloids on ADP, Collagen, Arachidonic acid-induced Platelet 
Aggregation. ....................................................................................................... 63	
Table 3-2 Cytotoxic effects of vanilloids and endovanilloids on platelets. ............... 65	
 
 
 
 
 
 
 
 
 
 
 
	 ix
 
List of Abbreviations 
AA  
APC  
ADP 
AEA 
2-AG 
ATP 
AUC 
CAP  
CGRP 
CB 
COX 
DHC 
DRG 
ELISA 
FVII 
FAAH 
GPCRs 
GP 
2-HPETE 
5-HT 
5-iodo-RTX 
IP3 
JAMs 
Arachidonic acid 
Activated protein C 
Adenosine diphosphate 
N-arachidonoyl-ethanol-amide 
2-Arachidonylglycerol  
Adenosine triphosphate 
Area under curve  
Capsaicin 
Calcitonin gene-related peptide  
Cannabinoid receptors  
Cyclooxygenase 
Dihydrocapsaicin  
Dorsal root ganglia 
Enzyme-linked Immunosorbent Assay  
Factor VII 
Fatty acid amide hydrolase 
G protein-coupled receptors 
Glycoprotein 
12-Hydro-peroxyeicosatetraenooic 
5-Hydroxytryptamine 
5-Iodo-resiniferatoxin  
1,4,5- Inositol triphosphate     
Junctional adhesion molecules  
	 x
LDH 
LDL 
Max 
MAGL 
NADA 
OLDA 
OCS 
PIP2 
PLC 
PLG 
PAI-1 
PDGF 
PECAM-1 
PF4 
PRP 
PPP 
PAR 
PKC 
SD 
SEM 
β-TG 
THC 
TAFI 
TxA2 
TF 
Lactate dehydrogenase 
Low-density lipoprotein  
Maximum aggregation   
Monoacylglycerol lipase  
N-arachidonoyl-dopamine 
N-oleoyldopamine   
Open canalicular system  
Phosphatidylinositol-4,5-bisphonate  
Phospholipase C 
Plasminogen  
Plasminogen activator inhibitor-1  
Platelet derived growth factor  
Platelet endothelial cell adhesion molecule 1  
Platelet factor 4 
Platelet rich plasma 
Platelet poor plasma  
Protease-activated receptor  
Protein kinase C  
Standard deviation 
Standard error of the mean 
β-thromboglobulin 
Delta-9-tetrahydrocannabinol  
Thrombin-activatable fibrinogen inhibitor 
Thromboxane A2  
Tissue factor 
	 xi
TFPI 
tPA 
TRPV1 
TM 
uPA 
vWF 
Tissue factor pathway inhibitor  
Tissue plasminogen activator  
Transient receptor potential vanilloids 
Transmembrane 
Urokinase 
Von Willebrand factor 
 
 
	  
	 xii
Abstract 
Capsaicin, the ‘hot’ principle found in chilli, and other vanilloids exert their effects 
on neuronal cells through activation of transient receptor potential vanilloid 1 
(TRPV1). TRPV1 is widely distributed in neuronal and non-neuronal cells. It has 
been proposed that consumption of vanilloid-like agents, including capsaicinoids, 
inhibits platelet aggregation and may protect against the development of 
cardiovascular disease. The aim of this study was to investigate the effects of a range 
of vanilloid-like agents on in vitro platelet aggregation. 
 
Venous blood was collected from healthy subjects who avoided antiplatelet 
medications and dietary chilli for at least 10 and 2 days, respectively. Collagen (4 
and 8 g/mL), ADP (10 and 5 μM) and arachidonic acid (AA) (300 and 400 mg/mL) 
-induced platelet aggregation was determined using platelet rich plasma (PRP; 
250x109/L) in the absence and presence of the capsaicinoids [capsaicin and 
dihydrocapsaicin (DHC)] and the endocannabinoid/endovanilloid agents [N-
oleoyldopamine (OLDA) and N-arachidonoyl-dopamine e (NADA)]. %Maximum 
aggregation (%Max), % area under curve (%AUC) and slope of platelet aggregation 
were determined. Platelet lactate dehydrogenase (LDH), which is released rapidly 
after cell membrane damage, was investigated to determine the direct toxic effects of 
these agents on platelets. Platelet factor 4 (PF4) and β-thromboglobulin (β-TG) 
release were examined to determine the effects of vanilloids on alpha granule 
release. Finally, the effects of TRPV1 antagonist (SB-452533) on capsaicin- and 
OLDA-mediated inhibition of ADP-induced platelet aggregation were investigated. 
 
	 xiii
ADP-induced (5 μM) platelet aggregation was inhibited in a concentration-dependent 
manner by capsaicin (%Max, meanSEM; 0 vs 100 μM, 83.80.9% vs 45.22.4%, 
n=6, p0.001); OLDA (0 vs 100 μM, 71.68.2% vs 9.41.4%, n=4, p0.001); and 
NADA (0 vs 100 μM, 71.55.9% vs 38.21.4%, n=4, p0.008). Similar results were 
observed using 10 μM ADP. OLDA and NADA, but not capsaicin and DHC, 
inhibited platelet aggregation induced by 4g/mL collagen: OLDA (Max%, 0 vs 100 
μM, 89.31.4% vs 45.512.5%, p<0.001); and NADA (0 vs 100 μM, 87.70.8% vs 
28.58.2%, p<0.001). AA-induced (300 mg/mL) aggregation was inhibited in a 
concentration-dependent manner by capsaicin (Max%, 0 vs 100 μM, 89.60.9% vs 
110.8%, p<0.001); DHC (0 vs 100 μM, 88.32.1% vs 18.76.9%, p<0.001); and 
NADA (0 vs 100 μM, 841.8% vs 21.94.7%, p<0.001). Similar results were 
observed using 400mg/mL AA. The inhibition of platelet aggregation by all agents 
was not due to direct toxic effects as LDH release from platelets was unaffected by 
any of the vanilloids. SB-452533 did not inhibit the effects of OLDA (SB-45253; 
Max 0 vs 10μM, 55.92.1% vs 58.41.37%) and capsaicin (SB-45253; Max 0 vs 
10μM, 65.150.44% vs 65.551%) on platelet aggregation, suggesting that 
inhibition of ADP-induced aggregation is not TRPV1 mediated. ADP-stimulated PF4 
release from platelets was impaired by capsaicin, DHC and OLDA whereas NADA 
enhanced ADP-stimulated PF4 release. Furthermore, OLDA and capsaicin impaired 
the release of β-TG from ADP-stimulated platelets. 
 
The present study using human platelet shows that capsaicin, DHC, OLDA and 
NADA inhibit in vitro aggregation.  The inhibitory effects of vanilloids are not 
TRPV1 mediated and not due to a direct toxic effect on platelets. Vanilloids may 
	 xiv
inhibit platelet aggregation by interfering with granule release, although further 
investigation of this possibility is warranted.  
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1.1 Introduction 
Platelets play an essential role in cardiovascular diseases both in pathogenesis of 
atherosclerosis and in the development of acute thrombotic events (Harker et al., 
1976, Zucker, 1980). Their importance in coronary disease and in acute coronary 
syndromes is indirectly confirmed by the benefit of antiplatelet agents in treating 
these disorders. Several research groups have studied natural compounds as potential 
antiplatelet agents. One of the exciting discoveries from these studies was that the 
active ingredient of the hot chilli pepper, capsaicin, inhibits in vitro platelet 
aggregation (Adams et al., 2009, Hogaboam and Wallace, 1991, Raghavendra and 
Naidu, 2009).  
 
The mechanism(s) by which capsaicin inhibits platelet aggregation is still poorly 
understood. To date only few studies have been conducted on human, rabbit and dog 
platelets to determine the effect of capsaicin and DHC on platelet aggregation and 
the mechanism(s) of its action(s) and those limited studies have produced conflicting 
data (Adams et al., 2009, Mittelstadt et al., 2012, Hogaboam and Wallace, 1991, 
Harper et al., 2009, Raghavendra and Naidu, 2009).  The effects of both endogenous 
and plant-derived vanilloid-like agents on in vitro human platelet aggregation and the 
potential mechanism(s) of action were therefore systematically investigated in this 
study. The aims were to: (1) investigate the effects of exogenous and endogenous 
vanilloids on in vitro   platelet aggregation, (2) determine whether vanilloid-like 
agents are toxic to platelets,  (3) determine effect of vanilloid-like agents on platelet 
alpha and dense granule release, and (4) investigate the potential involvement of 
TRPV1in mediating the anti-platelet effect of vanilloid-like agents.  
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1.2 Haemostasis 
The haemostatic response to blood vessel damage includes a series of interactions 
between platelets, the subendothelial matrix and coagulation proteins. Under normal 
conditions, endothelial cells prevent tissue factor (TF) and the subendothelial matrix 
from being exposed directly to platelets and coagulation proteins. The contact 
between platelets and the subendothelial matrix induces platelet activation to 
facilitate plug formation.  The haemostatic plug works as a catalytic surface for 
stimulation and recruitment of coagulation proteins, as well as localization and 
amplification of the coagulation system (Bombeli and Spahn, 2004, Hoffman, 2003, 
Hoffman and Monroe, 2001, Lawson and Murphy, 2004, Walsh, 2004). The 
haemostatic system is controlled by many anticoagulant proteins and inhibitors, as 
well as the fibrinolytic system. When working in balance, these systems ensure that 
the formed thrombus stops bleeding and that revascularization occurs afterward to 
maintain blood flow (Spahn and Rossaint, 2005).    
 
1.2.1 Platelets 
Platelets are small anuclear cytoplasmic fragments of megakaryocytes that are 
produced in the bone marrow (Avraham, 1993). Their major function is to maintain 
normal hemostasis and wound repair, but they also participate in many other 
pathophysiological processes such as atherosclerosis. Platelets possess many 
receptors that regulate platelet function (Ruggeri, 2002, De Botton et al., 2002).    
 
1.2.1.1 Platelet Structure and Function 
Platelets are small irregularly shaped cell fragments, with dimensions of 
approximately 3.0  0.5 m, an average volume of 6-8 femtoliters (fL) and exhibit 
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heterogeneity in size and structure. The circulating number of platelets in the 
peripheral blood ranges from 150-400  109/L (George, 2000). They play a major 
role in the physiological and pathological processes of hemostasis; wound healing, 
inflammation, host defense, and tumor metastasis (Jurk and Kehrel, 2005, Hoak, 
1988). The main components of platelets are alpha () granules, dense granules, the 
dense tubular system, open canalicular system (OCS), cytoplasmic membrane, 
mitochondria, peroxisomes, lysosomes and cytoskeleton (Table 1-1) (Kamath et al., 
2001, Fukami and Salganicoff, 1977). 
 
Table 1-1 Contents of Platelet Granules (Kamath et al., 2001) 
Electronic dense granules Alpha granules Lysosome  Peroxisomes 
ADP (metabolically inactive 
storage form)  
Serotonin  
ATP  
Pyrophosphate 
Calcium 
 
Fibrinogen 
Factor V  
Platelet derived growth 
factor (PDGF)  
Platelet specific proteins 
Platelet factor 4 
β-thromboglobulin  
Albumin 
Fibronectin  
Thrombospondin 
Hydrolytic 
enzymes 
 
Catalase 
 
Platelets are full of secretory granules that are crucial for their normal function 
(Coppinger et al., 2004). Dense granules store small molecules including serotonin, 
calcium ions and nucleotides, particularly adenosine triphosphate (ATP) and 
adenosine diphosphate (ADP). These constituents induce localized vasoconstriction 
and cause activation of other platelets, and any defect in their release may affect 
normal haemostasis (Ren et al., 2008). Platelets also contain other structures such as 
peroxisomes, that store catalase, and lysosomes that contain hydrolytic enzymes such 
as hexosaminidase and cathepsins, that may have a role in further platelet activation 
and clot remodeling (Kamath et al., 2001, Ren et al., 2008, Anitua et al., 2004).  
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The most abundant platelet secretory granules are -granules, accounting for ~10% 
of platelet volume, which is ten-fold more than dense granules. Furthermore, the 
total membrane surface area α-granules in a platelet is 14m, which is eight-fold 
more than dense granules and roughly equal to that of the open canalicular system. 
There are approximately 50-80 -granules per platelet and their size ranges from 
200-500nm (Frojmovic and Milton, 1982). Moreover, the role of -granules in 
atherosclerosis, angiogenesis, host defense, inflammation, wound healing, 
malignancy, and antimicrobial have been well described (Table 1-2) (Blair and 
Flaumenhaft, 2009). 
 
1.2.1.2 Platelet Activation 
The process of platelet activation can be classified into three overlapping phases: 
initiation, extension and perpetuation (Hoffman et al., 2008). Although several 
agonists initiate platelet activation in vitro, in vivo activation is normally initiated by 
thrombin and collagen. Platelets can adhere to subendothelial matrix proteins such as 
collagen once the endothelium has been disrupted, with these proteins having an 
important role in platelet attachment and the amplification reaction (Table 1-3). The 
disrupted vessel wall captures and then activates platelets via exposed collagen 
attached to von Willbrand factor multimers, building a monolayer that aids thrombin 
generation and the subsequent aggregation of more platelets (Falati et al., 2003, 
Gross et al., 2005, Del Conde et al., 2005). Essential to these events are platelet 
surface receptors that assist the vWF-dependent binding of platelets, glycoprotein 
Ib/IX/V (GPIb-IX-V) and, to a lesser extent, integrin αIIbβ3 and subsequent 
intracellular signaling (through α2β1 and GPVI), which leads to the attraction of  
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Table 1-2 Platelet Alpha Granule Contents and Functions 
Functions Factors References 
Chemokines  CXCL1 (GRO-α), CXCL4 
(platelet factor 4), CXCL5 
(ENA-78), CXCL7 (PBP, β-
TG, CTAP-III, NAP-2), 
CXCL8 (IL-8), CXCL12 
(SDF-1α), CCL2 (MCP-1), 
CCL3 (MIP-1α), CCL5 
(RANTES 
(Brandt et al., 2000, 
Gleissner et al., 2008) 
Growth factors  Vascular endothelium growth 
factor (VEGF), Platelet-
derived growth factor (PDGF), 
Fibroblast growth factor 
(FGF), Epidermal growth 
factor (EGF), Hepatocyte 
growth factor (HGF), Insulin-
like growth factor (IGF) 
(Rendu and Brohard-Bohn, 
2001, Nurden et al., 2008) 
Angiogenesis inhibitors  TSP-1 (Jimenez et al., 2000) 
Pro angiogenic mediators  Angiopoietin, CXCL12 (SDF-
1α), Matrix metalloproteinases  
(MMP-1, -2, and -9) 
(Karshovska et al., 2007, 
Massberg et al., 2006) 
Complement and 
complement binding 
proteins  
Complement C3, Complement 
C4 precursor 
(Maynard et al., 2007) 
Adhesive receptors  GPIbα-IX-V (major receptor 
for fibrinogen), Integrin 
αIIbβ3, GPVI (collagen 
receptor) 
(Berger et al., 1996, Suzuki 
et al., 2003) 
Membrane bound proteins  Integrins (e.g., αIIb, α6, β3), 
Immunoglobulin family 
receptors (e.g. GPVI, Fc 
receptors, PECAM), Leucine-
rich repeat family receptors 
(e.g., GPIb-IX-V complex), 
Tetraspanins (e.g., CD9), 
Other receptors (CD36, Glut-
3), P-selectin 
(Suzuki et al., 2003, Nurden 
et al., 2004, Niiya et al., 
1987, Maynard et al., 2007, 
Berger et al., 1993) 
Coagulation factors and co-
factors  
Factors V, Factors XI, Factor 
XIII 
(Rendu and Brohard-Bohn, 
2001, Hayward et al., 1995, 
Jeimy et al., 2008, 
Kiesselbach and Wagner, 
1972) 
Inactive precursor  Thrombin, Prothrombin, High 
molecular weight kininogens, 
Plasminogen 
(Maynard et al., 2007, Rendu 
and Brohard-Bohn, 2001) 
Inhibitory proteases  Plasminogen activator 
inhibitor-1 (PAI-1), α2-
antiplasmin 
(Rendu and Brohard-Bohn, 
2001) 
Anticoagulants Antithrombin, C1-inhibitor (Blair and Flaumenhaft, 
2009) 
Adhesion molecules Fibrinogen, Von Willebrand 
factor (vWF), Fibronectin, 
Vitronectin, Thrombospondin 
(Cramer et al., 1988, 
Gralnick et al., 1985) 
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Table 1-3 Major Sub Endothelial Matrix Constituents that support Platelet Adhesion 
(Hoffman et al., 2005b) 
Matrix Constituent Comment 
Collagen Large family of proteins with certain members supporting 
platelet adhesion, aggregation, and secretion 
von Willbrand factor Large multimeric protein critical for the hemostatic function of 
platelet  
Fibronectin Dimeric or multimeric protein that supports attachment and 
spreading of platelets 
Thrombospondin-1 Trimeric protein exhibiting both adhesive an anti-adhesive 
properties 
Laminins  Protein supporting platelet attachment  
Microfibrils A fibular bundle of protein constituents found in certain 
matrices 
 
further platelets to extend on the endothelium and form a nidus for subsequent 
platelet-platelet interactions (Massberg et al., 2003). 
	
At the site of vessel injury, collagen receptors help the capture of fast-moving 
platelets, resulting in activation of platelets and reorganization of the cytoskeleton. 
Platelets flatten out and attach more closely to the exposed vessel wall. vWF 
enhances this event by increasing the binding site affinity of collagen for platelets 
(Massberg et al., 2003, Kato et al., 2003, Poole et al., 1997, Nieswandt et al., 2001, 
Nieuwenhuis et al., 1985, Sixma et al., 1997). In inflammatory and thrombotic 
diseases, platelet activation is initiated by thrombin through G protein-coupled 
receptors (GPCRs) of the protease-activated receptor (PAR) family.  The initiation 
step is sufficient to form a platelet plug but not to prevent bleeding (Hoffman et al., 
2008). 
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The second stage of platelet aggregation occurs when more platelets are recruited, 
activated and aggregate on top of the collagen-bound monolayer (Hoffman et al., 
2008). The secretion of agonists, such as thromboxane A2 (TxA2), thrombin and 
ADP, recruit further platelets to the site of injury and activate phospholipase C 
(PLC). The PLC isoform, PLCγ2, hydrolyzes phosphatidylinositol-4,5-bisphonate 
(PIP2) to form 1,4,5- inositol triphosphate (IP3) and diacylglycerol. IP3 raises the 
cytosolic Ca2+ concentration by opening Ca2+ channels in the platelet-dense tubular 
system. This leads to Ca2+ influx through the plasma membrane of the platelet 
(Nesbitt et al., 2003, Kulkarni et al., 2004). The most important cohesive interaction 
that maintains the adhesion between the platelets is the binding of vWF or fibrinogen 
to αIIbβ3. Locally secreted or circulating catecholamines result in vasoconstriction 
and enhance platelet activation by increasing the effects of other platelet agonists. 
The majority of platelet agonists exert their action to extend the platelet plug through 
GPCRs. The characteristics of GPCRs make them especially well-suited for this 
function.  Human platelets have almost 10 forms of Gα, which fall into the G12α, Giα, 
Gsα and Gqα groups (Offermanns, 2006).  
 
The last stage of perpetuation occurs when the platelet plug is stabilized to prevent 
premature disaggregation (Hoffman et al., 2008). The interactions between platelets 
can be indirect, for example polyvalent adhesive proteins bind to activate αIIbβ3 on 
other platelets, or direct, where one cell adhesion molecule links to adjacent platelet 
in trans. Theoretically, both mechanisms support an additional adhesive force and 
another source of intracellular signaling (Brass et al., 2005). The binding between 
αIIbβ3 and fibrin, fibrinogen or vWF provides the main cohesive strength that 
stabilizes the aggregated platelet (Shattil and Newman, 2004). Other adhesive 
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molecules aside from integrins support the adhesion and intracellular signaling such 
as, platelet endothelial cell adhesion molecule 1 (PECAM-1; CD31) (Newman and 
Newman, 2003), junctional adhesion molecules (JAMs) (Muller, 2003, Bazzoni, 
2003) and signaling lymphocytic activation molecule (SLAM; CD150) (Krause et 
al., 2000, Martin et al., 2001, Nanda et al., 2005). Platelet activation is thus a 
dynamic process where effector pathways and many receptors are controlling at each 
phase of platelet plugs (Hoffman et al., 2008). 
 
1.2.1.3 Platelet Receptors 
Several nomenclature systems have been used to classify platelet membrane proteins 
(Table 1-4) (Hoffman et al., 2008). The majority of platelet adhesive proteins belong 
to the integrin family, a broadly distributed group of heterodimeric cell surface 
molecules (having two subunits,  and ). Eight -subunits are known that display 
high sequence homology, ranging from 35% to 45% at the first amino acid sequence 
level and a common structural organization. The -subunits are also similar but show 
less extensive sequence identity (Hynes, 1992, Fitzgerald et al., 1987). Every -
subunit joins in a noncovalent complex with an -subunit to make an efficient 
adhesive protein receptor. A solitary -subunit can combine with many -subunits. 
The 1 and 3 (2 is reported to be present at low levels) are the major -subunits 
expressed on platelet, as well five -subunits (Table 1-5) (Philippeaux et al., 1996). 
The IIb3 integrin (GPIIb/IIIa) is restricted predominantly to platelets and 
megakaryocytes and plays a major role in platelet aggregation and several other 
platelet reactions (Grossi et al., 1988, Honn et al., 1992, Boukerche et al., 1989). 
GPIb-V-IX however, is not a member of the integrin family but is involved in 
platelet adhesion (Andrews et al., 2003). The major role of GPIb-V-IX in  
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Table 1-4 Platelet Receptors for Adhesive Protein (Hoffman et al., 2005b) 
Ligand  Receptor (s) Other Common 
Designation(s)  
Collagen  GPIa/IIa,  
GPIIb/IIIa, IIb3 
GPIV 
GPVI 
VLA-2 
 
GPIIIb, CD36 
Fibrinogen  GPIIb/IIIa, IIb3 
Vitronectin receptor, v3 
 
Fibronectin  GPIc/IIa, 51 
GPIIb/IIIa, IIb3 
VLA-5 
Thrombospondin  Vitronectin receptor, v3 
GPIV 
Integrin-associated protein  
 
GPIIIb, CD36 
IAP 
Vitronectin  Vitronectin receptor, v3 
GPIIb/IIIa, IIb3 
 
von Willebrand factor  GPIb/IX 
GPIIb/IIIa, IIb3 
 
Laminin  GPIc/IIa region, 61 VLA-6 
 
	
	
Table 1-5 Platelet Integrins (Hoffman et al., 2005b)	
Integrin  Major Ligand (s) 
21 (GPIa/IIa, VLA-2) Collagen 
51 (GPIc/IIa, VLA-5) Fibronectin  
IIb3 (GPIIb/IIIa) Fibrinogen, fibronectin, vitronectin, von Willebrand factor, 
CD40L 
v3 (vitronectin receptor) Fibrinogen, fibronectin, vitronectin, von Willebrand factor, 
thrombospondin, osteopontin 
61 (GPIc/IIa region) Laminin  
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haemostasis can be traced directly to its function as the vWF receptor as well as a 
binding site for thrombin (Moroi et al., 1982, Okumura and Jamieson, 1976). 
Therefore, by adhesion with matrix proteins, vWF mediates directly reversible and 
rapid platelet adhesion that supports the rolling of platelets along the surface of the 
disrupted endothelium (Sadler, 2002). The most likely receptors responsible for the 
firm platelet-adhesive bound that enduringly stops the rolling of the platelet are 
integrins. A significant consequence of occupancy of GPIb-V-IX by vWF is the 
stimulation of intracellular signaling events that lead to the activation of IIb3 and 
platelet aggregation (Berndt et al., 2001, Savage et al., 1992). 
 
Collagen in the subendothelial matrix is an important initiator of platelet responses. 
It is both a substrate for platelet adhesion and a potent platelet agonist. Platelets have 
four types of collagen receptors. Two bind directly to collagen (21 and GPVI), 
and two bind to collagen through vWF (IIb3 and GPIb-IX-V). GPVI acts as the 
primary collagen receptor and is responsible for platelet secretion and aggregation 
induced by collagen. In addition, 21 works as an anchor for platelets to adhere to 
exposed collagen after endothelial injury (Hoffman et al., 2005a, Hoffman et al., 
2008, Clemetson et al., 1999).  
	
ADP is another platelet agonist that causes shape change of platelets from smooth 
discoid shape to speculated spheres, liberation of granule contents and release of 
thromboxane A2, ultimately causing platelet aggregation (Jin et al., 1998). ADP is 
released actively from the platelet dense granules in response to the physiological 
platelet agonists, which are thrombin, TXA2 and collagen, and amplifies its own 
effects as well as those of other activators, by a positive feedback mechanism 
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(Shankar et al., 2006, Maffrand et al., 1988, Born, 1985). Damaged vessel walls 
(endothelial cells) and erythrocytes also release ADP passively, which induces 
aggregation of platelets through integrin IIb3	activation and subsequent fibrinogen 
binding (Mills, 1996). ADP mediates platelet aggregation via binding to two G-
protein-coupled receptors subtype, P2Y1 and P2Y12 (Figure 1-1) (Jantzen et al., 
1999, Daniel et al., 1998). Activation of P2Y1 is sufficient to cause platelet shape 
change, while co activation of both P2Y1 and P2Y12 is required to induce platelet 
aggregation (Paul et al., 1999, Jin et al., 1998, Jin and Kunapuli, 1998, Savi et al., 
1998). 
 
The P2Y1 receptor is coupled to the heterotrimeric protein Gq. P2Y1 activation leads 
to activation of phospholipase C, production of diacylglycerol and inositol phosphate 
(IP). Moreover, calcium mobilization from cytosolic stores in response to IP 
formation results in activation of protein kinase C (PKC) and phosphorylation of 
myosin light chain, signaling events that play a major role in agonist-induced platelet 
shape change (Daniel et al., 1998, Daniel and Adelstein, 1976, MacKenzie et al., 
1996). ATP weakly antagonizes these effects of ADP at the P2Y1 receptor, in 
comparison to strong P2Y1 receptor-specific adenine nucleotide analog antagonists, 
A3P5PS, A3P5P, and A2P5P. These three antagonists are required in high 
concentrations (20-fold molar excess) to block functional responses to 10mM ADP, 
while a 200-fold molar excess of ATP is required to completely inhibit the P2Y1 
receptor (Boyer et al., 1996, Eckly et al., 2001). The absence of P2Y1 in mouse 
models of thrombosis has been shown to increase survival after the administration of 
platelet agonists and TF (Woulfe et al., 2001a, Leon et al., 1999, Leon et al., 2001). 
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1.2.2 Blood Coagulation 
The blood coagulation system contributes to the stabilization of the primary platelet 
plug. Natural endogenous anticoagulants regulate blood coagulation to ensure that, 
under normal conditions, haemostasis remains balanced. Any disturbance of this 
balance between coagulation and anticoagulation due to acquired or genetic factors 
may cause bleeding or thrombosis (Dahlback, 2000). 
 
1.2.2.1 Tissue Factor Pathway 
Blood coagulation is initiated by the exposure of TF, which is present in the cells that 
encircle the vascular bed as well as expressed by cells circulating in the blood such 
as leukocytes. TF binds to factor VII (FVII) and the activated form of FVII (FVIIa). 
The TF-FVIIa complex triggers the conversion of FIX and FX to FIXa and FXa 
respectively (Kirchhofer and Nemerson, 1996, Mann et al., 1998). FIXa and FXa 
remain attached to the TF-bearing cell or diffuses into the blood to adhere to 
activated platelets (Hoffman et al., 1996). Platelet activation is combined with the 
disclosure of negatively charged phospholipids which have high affinity to bind and 
assemble enzyme-cofactor complex and coagulation factors that are essential for 
effective propagation of the system (Zwaal et al., 1998). 
 
The prothrombinase complex, which is a phospholipid-bound complex composed of 
FV and FXa, activates prothrombin to thrombin. Thrombin is a key enzyme in the 
coagulation system due to its multiple roles including platelet activation, fibrinogen 
to fibrin conversion and feedback amplification of coagulation (Figure 1-2). 
Thrombin activates FV, FVIII and FXI as feedback amplification. Another 
amplification loop is activation of FX by thrombin resulting in additional generation 
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of factor IXa that can lead to activation of factor X. vWF is an important adhesive 
protein for the creation of the primary platelet plug and FVIII circulates bounding to 
this factor. FVIII become activated and dissociated from vWF and make a complex 
with FIXa on the platelet surface, which eventually leads to FX activation (Gailani 
and Broze, 1991). Following fibrin clot formation, thrombin generation reaches its 
peak (Mann et al., 1998), which is important for the activation of FXIII and 
thrombin-activatable fibrinolysis inhibitor (TAFI) as well as for further fibrin 
generation (Davie, 1995). 
Thrombin generation is considered to be more important than fibrin deposition due to 
the fact that thrombin plays an important role in the activation of platelets, which is a 
crucial reaction for haemostasis response to vascular injury (Dahlback, 2000). 
 
 
Figure 1-2 Schematic Diagram of the Coagulation Cascade 
The initiation of blood clot formation occurs following vascular injury and the 
exposure of tissue factor (TF) to circulating blood. Thrombin exerts positive feedback 
regulation (dotted lines) by activating platelets and other procoagulant proteins. 
Activated platelets provide a phospholipid (PL) surface that serves to enhance enzyme 
complex formation. Platelet aggregates are anchored to damaged endothelium by von 
Willebrand Factor (vWF) (Gentry, 2004) 
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1.2.2.2 Natural Inhibitors of Blood Coagulation 
The coagulation system is controlled by three natural anticoagulants, the protein C 
anticoagulant system, tissue factor pathway inhibitor (TFPI) and antithrombin 
(Hoffman et al., 2008). Protein C is activated by thrombin and its cofactor 
thrombomodulin, to form activated protein C (APC). Thrombin alone is inefficient in 
activating protein C without its cofactor thrombomodulin; this complex increases the 
rate of protein C activation by 1000-fold. The protein C system inhibits the 
coagulation by controlling the activities of FVa and VIIIa, cofactors of the 
prothrombinase and tenase complexes, respectively (Dahlback and Villoutreix, 2005, 
Esmon, 2003, Nicolaes and Dahlback, 2002). Protein S and FV stimulate the activity 
of APC. Protein S is enough to inhibit activated factor V, while for regulation of 
activated factor VIII needs a synergistic APC cofactor function of both factor V and 
protein S (Nicolaes and Dahlback, 2002). 
 
TFPI is the major inhibitor of TF-VIIa complex and plays an important role in 
regulating thrombin generation (Broze, 1995).  TFPI inhibits activated factor VII by 
two mechanisms. Firstly, TFPI binds to and inhibits activated factor X that has been 
activated via TF-activated factor VII. Secondly, the complex of TFPI-activated factor 
X binds to TF-activated factor VII building an inactive quaternary complex 
(Hoffman et al., 2008). Heparin binds to antithrombin (AT) causing conformational 
change, which makes AT more reactive to thrombin, activated factor X and activated 
factor IX (Silverman et al., 2001, Lane et al., 2005, Carrell et al., 1991, Schulze et 
al., 1994).  
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1.2.3 Fibrinolysis 
Fibrinolysis helps to balance coagulation to ensure blood flow and prevent bleeding 
(Degen, 2001, Esmon et al., 1999, Hajjar, 2003, Kolev and Machovich, 2003, 
Cesarman-Maus and Hajjar, 2005). Tissue plasminogen activator (tPA) and 
urokinase (uPA) are the major endogenous activators of fibrinolysis (Kasai et al., 
1985, Pennica et al., 1983). tPA and uPA convert the circulating plasma zymogen 
[plasminogen, (PLG)] to plasmin, which is the main fibrinolytic protease (Holvoet et 
al., 1985). Fibrin enhances plasmin generation by binding PLG and tPA on its 
surface to protect it against the inhibitor, 2-antiplasmin. The affinity between tPA 
and PLG is reduced in the absence of fibrin but increased in its presence. tPA has 
much higher affinity for fibrin than uPA, but uPA is an effective PLG activator in the 
presence and the absence of fibrin (Gurewich et al., 1984, Lijnen et al., 1986). 
 
2-Antiplasmin is the major plasmin inhibitor, which immediately neutralizes 
plasmin in the flowing blood or in the vicinity of a platelet-rich thrombus (Holmes et 
al., 1987). In addition, plasmin activity is inhibited by 2-macroglobulin, but to a 
lesser extent compared to 2-antiplasmin (Aoki et al., 1978). Plasminogen activator 
inhibitor-1 (PAI-1) is the most important and rapidly acting inhibitor of tPA and uPA 
(Ny et al., 1986, Samad et al., 1996). Activated thrombin-activatable fibrinogen 
inhibitor (TAFI) is a potent attenuator of fibrinolysis (Eaton et al., 1991, Nesheim, 
2003). There are two kinds of fibrinolytic receptors, activation and clearance 
receptors. These receptors include IIb3, integrin M2, -enolase, annexin 2, 
Heymann nephritis antigen and amphoterin which are expressed on platelets, 
leukocytes, monocytoid cells, endothelial cells, renal epithelial cells and 
neuroblastoma cells respectively (Hajjar, 1995). 
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1.3 Cannabinoid Receptors 
The endocannabinoid system is composed of the cannabinoid receptors (CB), 
endogenous cannabinoids (endocannabinoids) and enzymes that degrade and 
synthesis endocannabinoids (Howlett et al., 2002, Freund et al., 2003, Mackie, 
2006).  Endocannabinoid effects are mostly mediated by two G protein-coupled 
receptors (GPCRS), CB1 and CB2, even though other receptors might be involved 
such as TRPV1 (Howlett et al., 2002). CB1 receptors are mainly present in several 
brain regions and peripheral nerves and mediate retrograde synaptic inhibition of 
endocannabinoids (Herkenham et al., 1991, Matsuda et al., 1993, Marsicano and 
Lutz, 1999).  CB2 receptors have a limited distribution, being present in some 
immune cells, some neurons and inflammatory cells (Galiegue et al., 1995, Van 
Sickle et al., 2005, Ofek et al., 2006). 
 
In addition, CB1 and CB2 receptors are present in platelets but their role in platelet 
activation is unclear. Delta-9-tetrahydrocannabinol (THC) is a main compound of 
marijuana (natural cannabis) and it activates platelets by increasing P selectine and 
glycoprotein IIb-IIIa expression and not through activation of CB1 or CB2 (Deusch 
et al., 2004). Furthermore, it increases 2-arachidonylglycerol (2-AG) levels, resulting 
in activation of platelets through the AA pathway (Nakahata, 2008). A further study 
has shown that anandamide activates rabbit platelets through the same pathway 
(Braud et al., 2000). Both studies showed that it is not CB1 or CB2 mediated. On the 
other hand, it has been reported that anandamide (arachidonoylethanlamide, AnNH) 
activates human platelets through a mechanism independent of the AA pathway 
(Maccarrone et al., 1999). Later, the same group showed that 2-AG mediated 
aggregation via an uncharacterized CB receptor (MacCarrone et al., 2001). 
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CB1 and CB2 are similar to other GPCRs, depending on pharmacological influences, 
such as functional selectivity (Breivogel and Childers, 2000, Prather et al., 2000, 
Mukhopadhyay and Howlett, 2005, Urban et al., 2007), partial agonism (Straiker and 
Mackie, 2006) and inverse agonism (Vasquez and Lewis, 1999, Kenakin, 2001, 
Kenakin, 2007), which play a significant role in regulating the cellular response to 
specific cannabinoid receptor ligands (Mackie, 2008). 
 
1.3.1 Endogenous Cannabinoids (Endocannabinoids) 
Endocannabinoids include ‘endovanilloids’ mentioned later, such as the AA 
derivatives and eicosanoid family members, 2-arachidonylglycerol (2-AG), N-
arachidonoyl-dopamine (NADA), anandamide (N-arachidonoyl-ethanol-amide, 
AEA), O-arachidonoyl-ethanolamine (virodhamine) and 2-arachidonylglyceryl-ether 
(noladin ether) (Figure 1-3) (Blankman et al., 2007). In comparison to other chemical 
signals in the brain, endocannabinoids are not produced and stored in the neural cells 
but synthesized on demand from their precursors and then released (Simon and 
Cravatt, 2006, Alexander and Kendall, 2007, Basavarajappa, 2007, Okamoto et al., 
2007).  
 
Anandamide shares with capsaicin the ability to stimulate TRPV1. The main 
endocannabinoids, anandamide and 2-AG, are produced in response to an increasing 
concentration of intracellular calcium by diacylglycerol lipase, and are degraded and 
hydrolyzed by two enzymes, fatty acid amide hydrolase (FAAH) and 
monoacylglycerol lipase (MAGL) (Blankman et al., 2007, Bisogno, 2008). 2-AG 
hydrolysis produces AA that is the main substrate for cyclooxygenase (COX) 
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1.4.2 TRPV1 Function  
There are several amino acids and amino acid sequences of the TRPV1 protein that 
have defined functions, such as mediating capsaicin action, heat activation, 
phosphorylation and modulation by lipids, multimerization, proton action, 
permeability and desensitization. TRPV1 is therefore fundamental in peripheral 
nociception. Understanding the sequences and amino acids of TRPV1 could lead to 
the development of anti-nociceptive or anti-inflammatory agents (Tominaga and 
Tominaga, 2005). 
1.4.2.1 Capsaicin Action 
Capsaicin is structurally related to endogenous TRPV1 agonists, such as N-
arachidonyl dopamine (NADA), 12-hydro-peroxyeicosatetraenooic (12-HPETE) and 
anandamide (Huang et al., 2002, Hwang et al., 2000, Zygmunt et al., 1999). 
Capsaicin and its congeners, for example RTX, are lipophilic, which allows them to 
pass through the cell membrane and act on binding sites on the intracellular domain 
of TRPV1, providing a possible explanation for the lag time between capsaicin 
intake and pungent sensation (Jung et al., 1999). TRPV1 has a similar structure to 
voltage-gated K+ channels, involving the six-TM topology. As specified by the 
contemporary helix-packing models of the voltage-gated K+ channels, the first, 
second and third TM domains are placed on the lipid-facing side of the tetrameric 
channel complex. In contrast, the fifth and sixth TM domains are placed nearer to the 
pore-forming channel core. Presuming TRPV1 is similar to helix packing, the 
capsaicin lipophilic moiety might bind to the second and third TM domains on the 
channel-lipid interface.  The vanilloid moiety might interact with residues around 
Tyr 511 in the cytosolic region, therefore binding the cytosolic tail with two TM 
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domains (Kuzhikandathil et al., 2001, Tominaga and Tominaga, 2005, Welch et al., 
2000). 
1.4.2.2 Heat Activation 
TRPV1 heat-evoked currents exhibit similar characteristics to those of capsaicin-
evoked currents. However, the TRPV1 responses to heat and capsaicin are different, 
although the mechanisms overlap. Several TRP family ion channels (TRP 
(melastatin) 8 (TRPM8), TRP subfamily A member 1 (TRPA1), TRPV1, TRPV2, 
TRPV3, TRPV4) are thermosensitive, suggesting that the domains of temperature 
sensor are present in these protein channels (Jordt et al., 2003, Patapoutian et al., 
2003, Tominaga and Caterina, 2004). TRPV1 displays the property of voltage-
dependent gating, when it is activated by changes in temperature and depolarization, 
and results in graded shifts in its voltage-dependent activation curve (Gunthorpe et 
al., 2000). 
1.4.2.3 Phosphorylation 
TRPV1 is phosphorylated by kinases including protein kinase C (PKC), protein 
kinase A (PKA) and Ca2+|Ca2+M-dependent kinase II (CaMKII). Inflammatory 
mediators such as prostaglandins activate PKA-dependent pathway, which affects 
heat- or capsaicin- mediated effects on sensory nerve by acting on TRPV1 (Bhave et 
al., 2002, Mohapatra and Nau, 2003). In addition, it has been reported that PKA 
phosphorylates the Ser 116 and Thr 370 in the amino terminus, which leads to 
TRPV1 desensitization. Ser 116 phosphorylation by PKA suppresses TRPV1 
dephosphorylation induced by capsaicin exposure (Rathee et al., 2002). 
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TRPV1 receptor PKC-dependent phosphorylation results from activation of Gq-
coupled receptors via many inflammatory mediators including prostaglandins, ATP, 
bradykinin and tryptase or trypsin (Dai et al., 2004, Moriyama et al., 2003, 
Moriyama et al., 2005, Sugiura et al., 2002, Tominaga et al., 2001). PKC-dependent 
phosphorylation of TRPV1 decreases the temperature threshold for TRPV1 
activation plus potentiates proton- or capsaicin-evoked responses, such that normally 
non-painful temperatures (normal range) are able to stimulate TRPV1 and lead to 
painful sensation (Numazaki et al., 2002). CaMKII regulates the activity of TRPV1 
upon TRPV1 phosphorylation at Thr704 and Ser502 by controlling capsaicin 
binding. Therefore, TRPV1 phosphorylation via three different kinases appears to 
regulate the activity of the channel via the dynamic stability between 
dephosphorylation and phosphorylation processes (Jung et al., 2004). 
1.4.2.4 Modulation by Lipids 
Lipids derived from cell membranes are also known to regulate some ion channels, 
including TRPV1 (Ahern, 2003, Hwang et al., 2000, Zygmunt et al., 1999). 
Phosphatidylinositol-4,5-bisphonate (PIP2) seems to be associated with TRPV1, 
leading to ionic channel inhibition, while PIP2-mediated inhibition appears to be 
discharged upon stimulation of PLC via metabotropic receptors, resulting in 
hydrolysis of PIP2 to inositol (1,4,5) trisphosphate and diacylglycerol. PIP2 deletion 
from TRPV1 upon hydrolysis by PLC or experimental sequestration results in 
channel activation (Chuang et al., 2001). 
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1.4.2.5 Multimerization 
TRPV1, like many other TRP channels, has a carboxyl terminus consisting of a TRP 
domain near to the sixth TM and a long amino terminus consisting of three ankyrin-
repeat domains (Sedgwick and Smerdon, 1999). The ankyrin repeat is composed of a 
~33-residue motif labeled after ankyrin cytoskeletal protein, calmodulin (CaM) is a 
one protein that bind to the first ankyrin repeat domain of TRPV1 (Rosenbaum et al., 
2004, Sedgwick and Smerdon, 1999). TRPV1 forms multimers with a homotetramer 
as the predominant form and heterooligomerises with TRPV3, which is another heat-
sensitive TRP channel (Smith et al., 2002). 
1.4.2.6 Proton Action 
TRPV1 function is affected by acidification of the extracellular media in two ways. 
First, extracellular protons lower the threshold for TRPV1 channel activation, which 
increases the strength of capsaicin or heat as a TRPV1 agonist. Second, extracellular 
protons can act as an agonist by increasing the probability of opening the TRPV1 
channel at room temperature with further acidification (to pH <6.0) (Tominaga et al., 
1998). Mutational analysis has demonstrated that TRPV1 Glu 600, situated in 
extracellular putative domain, works as the main regulatory site for proton 
potentiation of TRPV1 activity, while Glu 648 is associated with direct proton-
evoked TRPV1 activation (Jordt et al., 2000). 
1.4.2.7 Permeability 
The TRPV1 shows remarkable preference for bivalent cations, however the cation 
permeability region in TRPV1 is not well defined (Welch et al., 2000, Caterina et al., 
1997). It exhibits high preference for Ca2+ with high relative permeability for Ca2+ 
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(Bevan and Szolcsanyi, 1990). Extracellular Ca2+ is an important factor in 
desensitization caused in presence of capsaicin (Holzer, 1991), therefore, it was 
found that elimination of extracellular Ca2+  in that it has decreased desensitization to 
capsaicin (Liu and Simon, 1996, Garcia-Hirschfeld et al., 1995). Moreover, any 
change in TRPV1 permeability to Ca2+ leads to loss of Ca2+-dependent 
desensitization in the presence of extracellular Ca2+ (Mohapatra et al., 2003). 
1.4.2.8 Desensitization 
Capsaicin has paradoxical effects, in that it has algesic and analgesic action. These 
may relate to the ability of capsaicin to desensitize nocieptive terminals after 
prolonged exposure (Szallasi and Blumberg, 1999, Caterina et al., 1997). 
Desensitization to capsaicin is a complicated process with different kinetic 
components. These are a “rapid” component that depends on Ca2+ influx through 
TRPV1 and a “slow” component, which does not (Docherty et al., 1996, Koplas et 
al., 1997, Liu and Simon, 1996, Piper et al., 1999).    
 
1.4.3 TRPV1 Distribution 
TRPV1 is widely distributed throughout the peripheral nervous system, central 
nervous system and non-neuronal tissue. TRPV1 is highly expressed in more than 
50% of human dorsal root ganglia (DRG) (Sanchez et al., 2001). It is more prevalent 
in small to medium sized neurons and TRPV1-like immunoreactivity has been 
demonstrated in thinly myelinated and unmyelinated fibers, conforming to the 
original hypothesis that TRPV1 was expressed mainly in nociceptors (Caterina and 
Julius, 2001). TRPV1 is also present in the spinal cord (mainly in sensory efferent 
fibers), several regions of the brain, such as substantia nigra, hippocampus and 
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hypothalamus (Sanchez et al., 2001), and non-neuronal tissues and cells such as 
bladder urothelium and smooth muscle (Birder et al., 2001), macrophages (Chen et 
al., 2003), liver hepatocytes (Reilly et al., 2003), pancreatic -cells, endothelial cells, 
lymphocytes (Lai et al., 1998), epithelial cells lining human airways, keratinocytes 
(Southall et al., 2003) and polymorphonuclear granulocytes (Heiner et al., 2003). 
Furthermore, lung (Kollarik and Undem, 2004), dental pulp (Renton et al., 2003), 
urinary bladder (Yiangou et al., 2001b), gastrointestinal tract (GIT) (Ward et al., 
2003) and prostate (Van der Aa et al., 2003), have fibres with TRPV1-like 
immunoreactivity, consistent with capsaicin-sensitive pathway distribution (Szallasi 
and Blumberg, 1999). Fluorescent labels have identified TRPV1 in more precise 
subcellular areas on the Golgi complex, cell membrane and smooth endoplasmic 
reticulum (Veronesi and Oortgiesen, 2006). 
 
1.4.4 Biochemical Pharmacology of TRPV1 
Expression of TRPV1 in DRG and its ability to mediate pain responses to vanilloids 
suggest that the expression of TRPV1 might be different in acute and chronic pain 
models in rat (Ji et al., 2002, Sanchez et al., 2001). It has been observed that the 
number of TRPV1-like immunoreactive fibres increases in the colon of patients with 
irritable bowel syndrome and active inflammatory bowel disease, and in rectal 
biopsy from patients with fecal urgency and rectal hypersensitivity (Chan et al., 
2003, Yiangou et al., 2001a). Moreover, the number of TRPV1 receptors in DRG 
increased after DRG avulsion injury (e.g. central axotomy) (Smith et al., 2002). This 
information suggest that upregulated TRPV1 expression might be related to certain 
types of pathophysiologies that lead to pain, providing support for the therapeutic 
potential of TRPV1 antagonists (Cortright and Szallasi, 2004). Abnormal expression 
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of TRPV1 by neurons that do not express TRPV1 normally has been associated to 
the occurrence of inflammatory hyperalgesia and neuropathic pain (Hudson et al., 
2001, Rashid et al., 2003). 
 
Activation of TRPV1 in neurons and non-neuronal tissues results in rapid increases 
in intracellular Ca+2 levels. Cloned TRPV1 does not discriminate between 
monovalent cations, but exhibits significant preference for those that are divalent 
(sequence of permeability:  Ca+2 >Mg+2 >Na+  K+  Cs+). The relative permeability 
of TRPV1 is very high to Ca+2 (PCa/PNa = 9.60; PMg/PNa = 4.99), which exceeds what 
has been observed for most non-selective cation channels (Mayer and Westbrook, 
1987, Seguela et al., 1993). In cultured sensory neurons, the continuous exposure to 
vanilloid leads to desensitization according to electrophysiological analyses of 
vanilloid-evoked response. However, in the absence of extracellular calcium, 
vanilloid–evoked responses showed little or no desensitization during continuous 
capsaicin application. Indeed, the response to capsaicin is depended on ambient 
calcium levels (Holzer, 1991, Liu and Simon, 1994). 
	
1.5 Vanilloids 
Capsaicinoids are the hot compounds in placental tissues of Capsicum fruits. They 
are responsible for capsicum’s pungency by eliciting a sensation of burning pain by 
selectively activating sensory neurons that convey the noxious stimuli to the central 
nervous system (Caterina, Schumacher et al. 1997; Aza-Gonzalez, Nunez-Palenius et 
al. 2010).  
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1.5.1 Endogenous Vanilloids 
TRPV1 is activated by endogenous AA derivatives that include the 
endocannabinoids, OLDA, NADA, N-acylethanolamines [N-oleoylethanolamine, 
anandamide, N-linoleoylethanolamine]; plus lipoxygenase products [e.g., leukotriene 
B4, 12-(S)- and 15-(S)-hydroperoxyeicosatetraenoic]. These substances have 
different affinities to TRPV1 and are increasingly recognized as an important group 
of signaling molecules affecting tissue injury, pain and inflammation (Zhong and 
Wang 2008). The most potent and selective endogenous TRPV1 agonist is OLDA, 
which is 30 times more potent than capsaicin, and 50 times more potent at TRPV1 
than at CB1 receptors. Furthermore, OLDA is metabolized (inactivated) slowly, 
suggesting it is a stable compound that may stay for hours in biomembranes and 
activate the receptors for longer periods. Moreover, it may function as a central or 
peripheral mediator of TRPV1 activation.  
 
NADA was the first endovanilloid identified. It has nanomolar potency to TRPV1 
and CB1, and is more potent than capsaicin but less so than OLDA. NADA is found 
in brain regions with high TRPV1 expression (i.e., DRG, hippocampus, striatum and 
cerebellum). The TRPV1 antagonists, capsazepeine and iodoresiniferatoxin, block 
the action of NADA (Chu et al., 2003, Zhong and Wang, 2008, Hu et al., 2009).  
 
1.5.2 Plant Derived Vanilloids  
There are many capsaicinoid analogs found naturally (Kozukue et al., 2005, 
Thompson et al., 2005a, Thompson et al., 2005b). The six most abundant analogs are 
DHC, capsaicin, homocapsaicin, homodihydrocapsaicin, nordihydrocapsaicin, and 
nonivamide (Figure 1-5) (Reilly et al., 2001a, Reilly et al., 2001b, Davis et al., 2007, 
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Mueller-Seitz et al., 2008). It has been well described that capsaicinoids are 
important agonists of TRPV1 (Caterina et al., 1999, Zygmunt et al., 1999, Bhave et 
al., 2002), and they may produce their effects through both receptor-dependent and 
receptor-independent pathways (Ziglioli et al., 2009). 
 
Each analog binds to and activates TRPV1, but with different potency depends upon 
alkyl chain structure (Hayes et al., 1984, Walpole et al., 1993a, Walpole et al., 
1993c, Walpole et al., 1993b) and a 3-methxy-4-hydroxybenzylamine (vanilloid) 
ring. The most pungent and potent analogs are capsaicin > nonivamide > DHC, 
followed by the other analogs (Reilly and Yost, 2006).  
 
Capsaicinoids are formed by condensing a branched fatty acid (from 9 to 11 carbon 
atoms) produced from either leucine or valine, to a molecule of vanillyllamine 
(Curry et al., 1999, Thiele et al., 2008) and are stable in nonpolar and polar solvents 
(Tanaka et al., 2009). It has been shown that capsaicinoids exert numerous beneficial 
physiological and pharmacological effects (Luo et al., 2011). However, capsaicinoids 
are also toxic to numerous cells through TRPV1-dependent and independent 
pathways with toxicity dependent on the route of administration (Glinsukon et al., 
1980, Lee et al., 2000, Maccarrone et al., 2000, Macho et al., 2000, Surh, 2002, 
Reilly et al., 2003, Agopyan et al., 2004, Reilly and Yost, 2005, Johansen et al., 
2006). 
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antagonists, 5-iodo-resiniferatoxin (5-iodo-RTX) and AMG 9810 in a concentration 
dependent manner. It was also reported that TRPV1 contributed to the activation of 
platelets by ADP and thrombin which presumably is due to formation of 
endovanilloids in response to the agonists (Harper et al., 2009).    
 
1.5.2.2 Clinical Applications of Plant-Derived Vanilloids 
Capsaicinoids have a number of therapeutic properties but have to date been limited 
by high toxicity and low selectivity (Luo et al., 2011). Examples include, 
antineoplastic action (Macho et al., 2003, Yang et al., 2010), pain relief (Wong and 
Gavva, 2009, Knotkova et al., 2008), anti-obesity, antinflammatory and antioxidant 
properties (Ramirez-Romero et al., 2000, Rosa et al., 2002, Sancho et al., 2002, Joo 
et al., 2010). 
1.5.2.2.1 Analgesia 
Capsaicin is the most studied capsaicinoid for pain relief. It has been found that 
administration of capsaicin locally or orally leads to reduced rheumatoid arthritis 
pain, inflammatory heat and noxious chemical hyperalgesia (Fraenkel et al., 2004). 
Furthermore, capsaicin is the main component in Adlea, which is a long-acting 
analgesic ointment used to treat osteoarthritis and post-surgical pain (Remadevi and 
Szallisi, 2008). Capsaicin is also added to many popular over-the counter creams as a 
pain reliever, at a concentration of 0.075% or less (Knotkova et al., 2008). Generally, 
the efficacy of capsaicin-containing creams to treat chronic pain is poor to moderate 
(Luo et al., 2011). Capsaicin is thought to exert pain relief by an initial irritation and 
excitation of sensory neurons with TRPV1 receptors, followed by the lasting 
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refractory state i.e. desensitization (Gerner et al., 2008, Kissin, 2008). That effect 
makes capsaicinoids unique compare to other natural irritants.  
1.5.2.2.2 Cancer Treatment   
The potential of capsaicin and DHC in treating cancer has been widely investigated 
in both in vitro and in vivo studies (Surh, 2002). In animal experiments, capsaicin 
reduced the size of MDAMB231 breast cancer masses in mice after oral 
administration by 50%, and effectively suppressed the growth of breast pre-
neoplastic lesions by up to 80%. In addition, systemic administration of capsaicin 
decreased MDAMB231 breast cancer tumors size by 80% (Thoennissen et al., 2010). 
Furthermore, capsaicin was able to arrest migration of the cultured breast cancer cell 
and destroy cultured prostate cancer cells, and DHC was reported to enhance the 
autophagy in cultured human HCT116 colon cancer cells (Oh et al., 2008, 
Thoennissen et al., 2010, Yang et al., 2010). Moreover, in clinical studies capsaicin 
was reported to suppress the development of leukemic cells expressing wild-type p53 
(Ito et al., 2004). 
 
It is well known that proliferation of cells plays the main role in carcinogenesis and 
is an important marker for cancer prevention.  The chemopreventive and anticancer 
effects of capsaicinoids are closely linked to their potential to inhibit cell 
proliferation and migration, and to induce apoptosis. Moreover, capsaicin and DHC 
have been found to suppress the development of different malignant cell lines by 
inducing apoptosis, cycle arrest, autophagy, and/or by the suppression of metabolic 
cellular activation (Zhang et al., 2003, Choi et al., 2010b, Choi et al., 2010a, Ghosh 
and Basu, 2010, Thoennissen et al., 2010).  It has been reported that capsaicin and 
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DHC might suppress an isoform of cytochrome P450, which is an enzyme associated 
with metabolic activation and detoxification of variant low-molecular-weight 
carcinogens (Singh et al., 2001). Interestingly, capsaicin selectively induces 
apoptosis or inhibits the growth of malignant or immortalized cell lines, while at the 
same dosage does not affect normal cell lines (Kim and Moon, 2004). The 
underlying mechanisms of this phenomenon are still poorly understood (Luo et al., 
2011).  
 
In contrast, chilli extracts or capsaicin may instead act as a tumor promoter or co-
carcinogen (Surh and Lee, 1996). Epidemiological studies have found that people 
who consumed chilli peppers in large quantities are at higher risk of stomach cancer 
than non-consumers. Moreover, capsaicin metabolites (such as the reactive phenoxy 
radicals) may affect DNA and trigger malignant transformation and mutagenicity 
(Baez et al., 2010). Thus, capsaicin has both chemopreventive and carcinogenic 
characteristics, which make it a ‘double edged sword’ (Luo et al., 2011). 
1.5.2.2.3 Weight Reduction 
It is well known that energy expenditure and thermogenesis play a major role in 
obesity regulation, and that chilli peppers are able to increase energy expenditure to 
produce a sensation of heat when eaten. Therefore, capsaicinoids are considered as a 
potential natural substance for obesity management (Cui and Himms-Hagen, 1992, 
Leung, 2008, Joo et al., 2010). In clinical studies and animal experiments it has been 
found that capsaicinoids suppress obesity by decreasing body fat accumulation (Shin 
and Moritani, 2007, Reinbach et al., 2009). 
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1.5.2.2.4 Gastrointestinal System 
It is well known that the gastrointestinal system is rich in capsaicin-sensitive sensory 
nerves, which are thought to play an important role in maintaining the integrity of the 
gastrointestinal mucosa against injury (Peng and Li, 2010). It has also been reported 
that capsaicinoids have a gastroprotective effects in various animal models with 
gastric ulcers induced by hydrochloric acid, aspirin, ammonia, indomethacin or 
ethanol (Szolcsanyi and Bartho, 2001, Mozsik et al., 2007). This effect is attenuated 
in the presence of a TRPV1 antagonist (Luo et al., 2011). Conversely, it has been 
demonstrated that the effects of capsaicinoids on gastrointestinal mucosa are either 
beneficial or harmful depending on the dose and/or duration of exposure (Wang et 
al., 2005). Low doses of capsaicinoids may stimulate gastric epithelial regeneration 
and augment the basal gastric mucosal blood flow and gastric mucus secretion, 
which are advantageous to gastrointestinal defense (Nishihara et al., 2002). However, 
high doses of capsaicinoids usually result in depletion of neurotransmitters and 
desensitization and damage of capsaicin-sensitive neurons, which may injure the 
gastrointestinal mucosa (Wang, Hu et al. 2005). 
1.5.2.2.5 Cardiovascular System  
There is growing evidence that capsaicinoids have many beneficial effects on the 
cardiovascular system (Harada and Okajima, 2009, Peng and Li, 2010). Capsaicin-
sensitive sensory neurons are present in the cardiovascular system and may play an 
important role in controlling cardiovascular function via release of neurotransmitters 
such as substance P and the vasorelaxant peptide (calcitonin gene-related peptide, 
CGRP) (Zvara et al., 2006, Peng and Li, 2010). In addition, studies have reported 
that capsaicin activates TRPV1 to stimulate the release of CGRP, providing a 
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protective effect on cardiovascular function (Peng and Li, 2010). However, high dose 
of capsaicin can have deleterious effects on the cardiovascular system due to 
depletion of CGRP from nerve endings (Peng et al., 2002a, Peng et al., 2002b). The 
antioxidant property of capsaicinoids also contributes to their beneficial effects on 
the cardiovascular system. It is believed that low-density lipoprotein (LDL) 
oxidation is the initiating factor for growth and progression of atherosclerotic 
plaques. It has been found in vitro that capsaicin and DHC were able to raise the 
LDL resistance to oxidation by slowing the initiation of oxidation and/or delaying 
the oxidation rate (Ahuja et al., 2006). In high fat-fed rats, it has been reported that 
serum total cholesterol and lipid peroxide levels are reduced following capsaicin 
treatment (Manjunatha and Srinivasan, 2006, Manjunatha and Srinivasan, 2007). In 
adult women and men, the resistance of serum lipoproteins to oxidation increased 
after four weeks of regular consumption of chilli (Ahuja and Ball, 2006). These 
findings reflect the antioxidant ability of capsaicinoids and their potential clinical 
usefulness on cardiovascular diseases prevention (Luo et al., 2011). 
1.5.2.2.6 Effects of Plant-Derived Vanilloids on Platelet Aggregation  
Recently, it has been reported that capsaicin inhibits in vitro platelet aggregation in a 
concentration-dependent manner, while DHC exhibits a bimodal effect on platelet 
aggregation, stimulating at 3.125 μM, and inhibiting from 25-100 μM (Adams et al., 
2009). Furthermore, it was shown that capsaicin inhibited platelet aggregation 
induced by different agonists (ADP, calcium ionophore and collagen) but to a lesser 
extend compared to AA (Raghavendra and Naidu 2009). The anti-haemostatic 
effects of capsaicinoids may potentially prevent and/or decrease the incidence of 
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cardiovascular disease risk. The exact mechanism(s) responsible for the effect of 
capsaicin and DHC on platelet aggregation are not well understood. 
 
Previous studies suggested that the anti-haemostatic effect of capsaicin and DHC 
was not through specific receptors (TRPV1) on the platelet, but through insertion 
into platelet plasma membrane and changing membrane ionic permeability and/or 
fluidity (Hogaboam and Wallace, 1991). A subsequent study reported that capsaicin 
inhibited platelet aggregation induced by AA in a concentration-dependent manner 
through inhibition of COX1 (Raghavendra and Naidu 2009). According to Adams et 
al., (2009), inhibition of platelet aggregation by capsaicin and DHC is unlikely to be 
mediated through interference with ADP receptors, because the platelet’s shape did 
not change following exposure to capsaicin or DHC. However, a recent study has 
reported that TRPV1 was present in human platelets, and capsaicin was able to 
induce a concentration-dependant raise in Ca2+ release and Ca2+ influx from 
intracellular platelet stores, which was suppressed by 5-iodo-resiniferatoxin and 
AMG 9810, the TRPV1 antagonists (Harper et al., 2009). Furthermore, TRPV1 was 
reported to contribute to the activation of platelets induced by ADP and thrombin, 
suggesting formation of endovanilloids in response to the platelet agonist (Harper et 
al., 2009). This finding is in conflict with other recent and earlier studies, which 
demonstrated that capsaicinoids inhibit platelet aggregation rather than activate 
platelet aggregation (Adams et al., 2009).  A recent study on canine platelets reported 
that capsaicin inhibits platelet aggregation induced by collagen in a concentration 
dependent manner. They used a TRPV1 antagonist (A-993610) and found that 
capsaicin inhibitory effects on platelet aggregation were not mediated via TRPV1 
(Mittelstadt et al., 2012). 
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1.5.2.3 Plant-Derived Vanilloid Toxicity  
Vanilloids have been shown to be lethal via all routes of exposure in animals with 
intravenous administration the most toxic (Glinsukon et al., 1980). They have been 
widely known for a long time to cause coughing, respiratory inflammation, and 
severe irritation in experimental human and animals models. Capsaicin-induced cell 
death was greater in the cells that expressed more TRPV1, suggesting that TRPV1 
might be a key mediator of capsaicin-cytotoxic effects in these cells (Reilly, Taylor 
et al. 2003). In addition, there are many hypotheses to describe the mechanism(s) of 
bronchial epithelial cell death (Kedei et al., 2001, Grant et al., 2002, Reilly et al., 
2005). The cytotoxic effects of capsaicinoids in peripheral sensory (A and C-fiber) 
neurons has been reported (Szallasi and Blumberg, 1999) and used for chronic pain 
treatment (McMahon et al., 1991). 
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1.6 Project Aims     
The overall aim is to investigate the effects of vanilloid-like agents, including plant-
derived vanilloids (capsaicin and DHC) and endogenous vanilloids (OLDA and 
NADA) on platelet aggregation. 
 
The specific aims are to: 
1. Determine the in vitro effects of vanilloid-like agents on platelet aggregation 
induced by different platelet agonists, namely, ADP, collagen and AA. 
2. Determine the effects of transient receptor potential vanilloid (TRPV1) 
antagonist with vanilloids on platelet aggregation induced by ADP. 
3. Determine the potential direct toxic effects of vanilloids on platelets. 
4. Determine the effects of vanilloids on platelet alpha granule release. 
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Chapter 2  Materials and Methods 
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2.1 Ethics 
This study was approved by the Human Research Ethics Committee (Tasmanian) 
Network (Ref No: H0011414). Informed consent was obtained from each subject in 
accordance with the Declaration of Helsinki of the World Medical Association. 
	
2.2 Materials 
Reagent Supplier Location 
Adenosine diphosphate 
Arachidonic Acid 
Collagen 
Helena Laboratories Beaumont, 
Texas, USA 
Capsaicin 
N-arachidonoyl-dopamine  (NADA) 
N-oleoyldopamine (OLDA) 
SB452533 (N-(2-Bromophenyl)-N'-[2-
[ethyl(3-methylphenyl)amino]ethyl]-urea) 
Tocris Bioscience Bristol, UK 
Dihydrocapsaicin Sigm-Aldrich 
Pty.Ltd  
NSW, Australia 
Beta-Thromboglobulin ELISA Kit 
Platelet Factor 4 ELISA Kit 
Uscn Life Science 
Inc. 
Wuhan, China 
Serotonin ELISA Kit  
 
Labor Diagnostika 
Nord GmbH & 
Co.KG 
Nordhorn, 
Germany 
LDH Cytotoxicity Detection Kit Clontech 
Laboratories 
Mountainview, 
CA, USA 
All other reagents Sigma-Aldrich Pty 
Ltd 
NSW, Australia 
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2.2.1 Preparation of Platelet Aggregation Agonists 
ADP and AA were dissolved in deionized water and stored in 1M aliquots at -20C 
until needed. Aliquots of agonists were thawed and diluted in normal saline (pH 7.1) 
to produce final concentration of ADP (5 and 10M), AA (300 and 400mg/mL) and 
collagen (4 and 8g/mL).  
 
2.2.2 Preparation of Vanilloids 
Capsaicin, DHC and OLDA were dissolved in 100% ethanol and stored as 0.1M 
aliquots at -20C.  NADA was stored as 11.37 x 103μM aliquot at -20C. Aliquots of 
all vanilloids were diluted as required in normal saline (pH 7.1) to provide final 
incubation concentrations ranging from 3.125-100μM. The TRPV1 antagonist 
SB452533 was dissolved in 100% ethanol and stored in 10M aliquot at -20C and 
diluted to provide final incubation concentrations (1 and 10M). 
	
2.3 Methods 
	
2.3.1 Platelet Aggregation 
2.3.1.1 Principle of Light Transmission Aggregometry 
Platelet aggregation testing measures the ability of various agonists to platelets to 
induce in vitro activation and platelet-to-platelet activation. Platelet rich plasma 
(PRP) is stirred in a cuvette at 37°C and the cuvette sits between a light course and a 
photocell. When an agonist is added the platelets aggregate and absorb less light and 
so the transmission increases and this is detected by the photocell. There are two 
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types of agonists, weak agonists such as ADP, and strong agonists such as collagen. 
Aggregation induced by weak agonists form primary and secondary waves, while 
strong agonists form only secondary waves. Sometimes, strong agonists act as weak 
agonists at low concentrations but weak agonists even at high concentrations do not 
act like strong agonists (White and Jennings, 1999). 
2.3.1.2 Sample Collection and Processing  
Venous whole blood was collected by venipuncture from forty-eight normal subjects 
(aged 18-65) with 21-gauge needles and 25-mL syringes. Samples were collected 
into 3.2% sodium citrate anticoagulant (1:9 ratio of anticoagulant to whole blood). 
Volunteers avoided aspirin and antiplatelet medications for at least 10 days and 
dietary chilli for at least 2 days before giving blood samples.  
 
After collection, specimens were centrifuged at 150g for 10 minutes in room 
temperature to obtain platelet rich plasma (PRP). Then the remaining blood was 
centrifuged at 2000g for 20 minutes in room temperature to obtain platelet poor 
plasma (PPP). The platelet count in PRP was determined using a Sysmex 1000i 
analyzer and adjusted to 250 x 109/L using PPP from the same donor. 
2.3.1.3 Effect of Vanilloids on Platelet Aggregation 
All experiments were conducted using the four-channel AggRAM platelet 
aggregation analyzer (Helena Laboratories, Beaumont, USA) at 600rpm and 37°C 
using PRP adjusted to 250 x 109/L with PPP from the same donor. 225μL of PPP 
was placed in a cuvette in order to zero the machine before each sample analyses. 
Subsequently, 225μL of PRP was activated with collagen (4 or 8g/mL), ADP (5 or 
	 44
10M) or AA (300 or 400mg/mL) in the presence and absence of capsaicin, DHC, 
NADA or OLDA (final concentrations (0-100M). The four cuvettes were placed 
into the corresponding slot in the AggRAM and the corresponding button was 
pressed and the counting down was started from 10 minutes, after 40 seconds the 
agonist with/without the vanilloid was added (no incubation). In each analysis zero 
level of vanilloid was used with the agonist in the first slot and three different 
concentrations in the others. Finally, data were calculated automatically by the 
aggregometer software (HemoRAM 1.1.0., Helena Laboratories, Taxas, USA), 
which are maximum percent of aggregation (%MAX, reflects the intensity of 
aggregation responses) percent of area under the curve (%AUC), slope (rate of 
aggregation) and lag time per second (reflects the time from adding the agonist until 
the aggregation started). 
2.3.1.4 Effect of SB-452533 on ADP-Induced Platelet Aggregation 
The TRPV1 antagonist SB-452533 (1 and 10μM), ADP (5μM) and capsaicin or 
OLDA (50μM) were added to PRP, after 40 seconds from the start of aggregation 
(no incubation). %MAX, slope and %AUC were determined by the aggregometer 
software (HemoRAM 1.1.0., Helena Laboratories, Taxas, USA). This experiment 
was done to investigate if a SB-452533 would have an effect on OLDA and/or 
capsaicin inhibitory effect on platelet aggregation induced by ADP. 
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2.3.2 Lactate Dehydrogenase (LDH) Cytotoxicity Assay 
2.3.2.1 Test Principle and Method 
The assays were performed according to manufacturer’s instructions, Briefly, LDH is 
a stable cytoplasmic enzyme that is present in all cells. When the cell membrane is 
damaged, LDH is released rapidly into the culture supernatant. The LDH 
cytotoxicity detection kit (Clontech Laboratories, USA) is a colorimetric assay to 
quantitate cytolysis/cytotoxicity, and is depend on the measurement of LDH released 
from damaged cells.  Samples and controls are placed to the appropriate flat-bottom 
96-well plate wells in triplicate and centrifuged to obtain cell-free culture 
supernatant.  The reaction mixture is added and incubated with the supernatant.  The 
reaction is stopped by the addition of HCL and the color change is measured 
spectrophotometrically at 490nm or 490nm (reference wavelength 690nm). The LDH 
concentration in the samples is calculated by subtracting the average background 
control value from the average absorbance values of controls and samples. Then 
subtract the low control value from the sample value and divide to the difference of 
high control and low control. 
 
2.3.3 Measurement of Alpha Granule Release 
The release of platelet factor 4 (PF4) and β-thromboglobulin (β-TG) from alpha 
granules were determined using ELISA. 
2.3.3.1 Test Principle and Method 
The assays were performed according to manufacturer’s instructions, Briefly, ELISA 
plate (USCN Life Science Inc., Wuhan, China) wells are pre-coated with monoclonal 
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antibody specific for PF4 or TG called biotin-conjugated polyclonal antibody. 
Standards and samples are placed to the appropriate microtiter plate wells, then 
Avidin conjugated to Horseradish Peroxidase (HRP) is added. A 3,3’,5,5’-
tetramethylbenzidine (TMB) substrate solution is added to all wells. The wells that 
contain PF4 or TG, biotin-conjugated antibody and enzyme-conjugated Avidin 
show a change in color. The enzyme-substrate reaction is stopped by the addition of 
a sulphuric acid (stop) solution and the color change is measured 
spectrophotometrically at 450nm. The PF4 or TG concentration in the samples is 
calculated by comparing the optical density (O.D.) of the samples to the standard 
curve.  
 
2.3.4 Statistical Analysis 
Data were plotted using GraphPad Prism (version 5; San Diego, CA, USA). All data 
were analysed statistically with repeated measures ANOVA using general linear 
modelling (STATA version 12SE, StataCorp, LP, USA). Post-estimation Holm test 
analysis was then used to adjust p values for multiple comparisons. P values < 0.05 
were considered significant. 
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Chapter 3  Results 
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(%MAX, 71.68.2 vs 9.41.4, p0.001); (%AUC, 58.37.2 vs 0.890.5, p0.001) 
and by 10M ADP (%MAX, 843 vs 12.62, p0.001); (%AUC 69.12.4 vs 
0.810.15, p0.001). At high concentrations of NADA platelet aggregation induced 
by 5M ADP was inhibited (%MAX, 71.55.9 vs 38.21.4, p0.008); (%AUC, 
58.84.3 vs 26.613.7, p=0.003) and by 10M ADP (%MAX, 744.7 vs 39.22.4, 
p0.001); (%AUC, 744.7 vs 39.22.4, p0.001) (Figure 3.3 A,B,D,E). The order of 
potency in inhibiting ADP-induced platelet aggregation was OLDA> NADA> 
capsaicin> DHC.  The slope of the aggregation curve for both 5 and 10 M ADP was 
significantly reduced at 100 M OLDA and at 100 M capsaicin for 5 M ADP 
(Figure 3.2-3.3 C,F).  For OLDA, this was most likely an artifact due to the near 
complete inhibition of aggregation at 100 μM.  The lag time for aggregation was not 
affected by any of the vanilloid agents tested (data not shown).  
Ethanol alone showed no effect on platelet aggregation induced by ADP (data not 
shown).  
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%AUC, 68.80.68 vs 19.77.3, P<0.001), and OLDA (89.31.4% vs 45.512.5%, 
p<0.001; %AUC, 69.91.1 vs 328.9, p< 0.001) (Figure 3.6 A,B,D,E).  
 
Lag times were non-significantly prolonged with a combination of 4g/mL collagen 
and vanilloids especially OLDA (2313.2s vs 74.521.8s) and NADA (Lag 2612s 
vs 72.831.2s) (Figure 3.7). The slope of the aggregation curve 4g/mL collagen 
was significantly reduced at 100 μM OLDA and NADA (Figure 3.6 C,F). 
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Capsaicin strongly inhibited platelet aggregation induced by 300mg/mL AA (0 vs 
100 μM; %MAX, 89.60.9 vs 110.8, p<0.001; %AUC, 68.22.5 vs 7.340.36, 
p<0.001) and by 400mg/mL AA (91.21 vs 2711.1, p<0.001; %AUC, 68.52 vs 
11.51.9, p<0.001). DHC significantly inhibited aggregation stimulated by 
300mg/mL AA (%MAX, 88.32.1 vs 18.76.9, p<0.001; %AUC, 67.43.2 vs 
10.22.8, p<0.001) and 400mg/mL AA (%MAX, 87.93.2 vs 37.819.4, p=0.037; 
%AUC, 65.92.6 vs 22.58.7, p<0.001). NADA inhibited platelet aggregation 
induced by 300mg/mL (%MAX, 841.8 vs 21.94.7, p<0.001; %AUC, 60.32 vs 
6.90.7, p<0.001) and 400mg/mL AA (%MAX, 89.92.7 vs 60.415.8, p<0.002; 
%AUC, 652.6 vs 4416, p=0.04) but to a lesser extend compared to the plant-
derived vanilloids, capsaicin and DHC. However, capsaicin, DHC and NADA 
inhibited aggregation induced by 400mg/mL AA in inconsistent manner (Figure 3.9-
3.10 A,B,D,E). 
 
The slope of the aggregation curve for both 300 and 400mg/mL AA was 
significantly reduced at 100 μM capsaicin and DHC (Figure 3.9 C,F).  Lag times 
were significantly decreased with a combination of 300mg/mL AA and plant-derived 
vanilloids capsaicin (33.59.7s vs 10.87.2s) and DHC (23.413.7s vs 10.94.3s). In 
addition, lag time was significantly prolonged with a combination of 400mg/mL AA 
and NADA (8.33.9s vs 39.215.2s) (Figure 3.11). Finally, at the highest 
concentration tested (100 μM), OLDA did not affect platelet aggregation induced by 
either 300 or 400mg/mL AA (Figure 3.10).  
 
Table 3-1 summarizes the effects of planet-derived vanilloids and endovanilloids on 
platelet aggregation induced by ADP, collagen and AA.  
	Figu
indu
(%M
unde
Point
to co
 
re 3-9 Eff
ced Platelet
ax, normalize
r curve (%AU
s are the mea
ntrol (i.e. 0M
ects of Pla
 Aggregatio
d to aggrega
C) (B,E) and
n ± SEM of 
 vanilloids)
nt-Derived
n. Data are p
tion in the a
 slope of the
4 experiment
 Vanilloids
resented as p
bsence of v
 propagation 
s, for CAP an
 on Arach
ercent maxim
anilloid) (A,D
phase of curv
d DHC. * P 
idonic Ac
um aggregat
), percent a
e (slope) (C,
<0.05 compa
60
	
id-
ion 
rea 
F). 
red 
	Figu
Aggr
norm
(%AU
mean
(i.e. 0
re 3-10 Effe
egation. D
alized to agg
C) (B,E) an
 ± SEM of 4
M vanilloid
cts of Endo
ata are pre
regation in th
d slope of the
 experiments,
s) 
vanilloids o
sented as p
e absence of 
 propagation 
 for NADA a
n Arachido
ercent max
vanilloid) (A
phase of curv
nd OLDA. * 
nic Acid-ind
imum aggre
,D), percent a
e (slope) (C,F
P <0.05 com
uced Plate
gation (%M
rea under cu
). Points are 
pared to cont
61
	
let 
ax, 
rve 
the 
rol 
	Figu
indu
SEM
contr
 
re 3-11 Eff
ced Platelet
 of 4 experim
ol (i.e. 0M v
ect of Van
 Aggregatio
ents, for CA
anilloids) 
illoids on t
n. Data are 
P, DHC, NA
he Lag-Tim
presented lag
DA and OL
e of Arac
 time. Points
DA. * P <0.
hidonic Ac
 are the mean
05 compared
62
	
id-
 ± 
 to 
	 63	
Table 3-1 Effect of Vanilloids on ADP, Collagen, Arachidonic acid-induced Platelet Aggregation.  
Agonist ADP (5M) 
 CON CAP CON DHC CON NADA CON OLDA 
% MAX 
 
83.80.9 45.22.4 ***  78.82.8 60.99.1 71.55.9 38.21.4 ** 71.68.2 9.41.4 *** 
% AUC 
 
70.30.8 31.03.5 *** 60.22.5 47.55.1  58.84.3 26.613.7 ** 58.37.2 0.890.5 *** 
Slope 
 
83.01.7 64.24.8  84.32.1 81.05.3  80.32.0 81.07.5 85.35.2 5.35.8 *** 
Agonist ADP (10M)
% MAX 
 
88.01.0 69.05.6 ** 73.92.8 60.94.6 ** 74.04.7 39.22.4 *** 84.03.0 12.62.0 *** 
% AUC 
 
73.51.1 56.05.4 ** 60.22.5 47.55.1 ** 74.04.7 39.22.4 *** 69.12.4 0.810.1 *** 
Slope 
 
90.21.1 78.52.4 84.32.1 81.15.3 82.76.0 82.54.8 86.85.0 23.36.0 *** 
Agonist Collagen (4g/mL) 
% MAX 
 
83.92.4 
 
84.31.0 89.41.3 90.41.0 87.70.8 28.38.2 *** 89.31.4 45.512.5 *** 
% AUC 
 
67.01.5 
 
67.70.7 70.61.2 72.30.8 68.80.68 19.77.3 *** 69.91.1 32.08.9 *** 
Slope 
 
104.68.9 99.63.5 98.27.7 118.612.5 108.74.1 24.79.5 *** 111.55.6 41.011.2 *** 
Agonist Collagen (8g/mL)
% MAX 
 
85.32.8 82.32.8 91.01.6 90.41.0 88.92.6 79.02.7 90.31.6 85.71.7 
% AUC 
 
69.61.8 68.51.9 73.02.6 72.30.8 72.41.8 61.73.0 72.01.4 67.41.9 
Slope 
 
11413.4 115.49.4 111.211.0 118.612.5 120.010.0 97.98.0 114.04.9 114.64.3 
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Table 3-1 (cont). Effect of Vanilloids on ADP, Collagen, Arachidonic acid-induced Platelet Aggregation.  
Agonist AA (300mg/mL) 
CON CAP CON DHC CON NADA CON OLDA CON 
% MAX 
 
89.60.9 11.00.8 *** 88.32.1 18.76.9 *** 84.01.8 21.94.7 *** 81.51.6 72.49.8 
% AUC 
 
68.22.5 7.340.36 *** 67.43.2 10.22.8 *** 60.32.0 6.90.7 *** 64.30.6 56.78.6 
Slope 
 
74.49.7 2.90.3 *** 58.414.4 4.20.6 *** 31.211.0 46.912.8 61.64.0 54.98.0 
Agonist AA (400mg/mL)
% MAX 
 
91.21.0 27.011.1 *** 87.93.2 37.819.4 * 89.92.7 60.415.8 ** 86.04.0 83.20.5 
% AUC 
 
68.52.0 11.51.9 *** 65.92.6 22.58.7*** 65.02.6 44.016.0 * 64.01.4 60.36.5 
Slope 
 
71.64.3 3.40.9 *** 62.010.8 6.32.0 * 36.912.6 66.711.0 54.98.7 57.312.3 
Data are presented as percent maximum aggregation (%MAX), percent area under curve (%AUC) and slope of the 
propagation phase of curve (slope). Data are the mean ± SEM of 4 experiments for (100M) capsaicin (CAP), 
dihydrocapsaicin (DHC), N-arachidonoyl-dopamine (NADA) and N-oleoyldopamine (OLDA). * P <0.05, ** P <0.01, *** P 
<0.001 compared to control (CON) (i.e. 0M vanilloids). 
	 65
 
3.4 Effect of SB-452533 on ADP-induced Platelet Aggregation  
To determine whether inhibition of ADP-induced aggregation by vanilloids was 
mediated by TRPV1, experiments were conducted in the presence of the TRPV1 
antagonist, SB-452533. SB-452533 did not affect the inhibition of ADP-induced 
aggregation by OLDA (%Max, 0 vs 10 μM, 55.92.1% vs 58.41.37%) or capsaicin 
(SB-45253; %Max, 0 vs 10 μM, 65.150.44% vs 65.551%), suggesting that 
inhibition of platelet aggregation by vanilloids is not TRPV1 mediated (Figure 3.12).  
 
3.5 Cytotoxicity Assay  
LDH release from platelets was not affected when exposed to ADP and/or capsaicin, 
DHC, OLDA and NADA up to 100M. Hence, at the highest concentration texted 
tested in platelet aggregation studies, vanilloids were not toxic to platelets (Table 3-
2). 
 
Table 3-2 Cytotoxic effects of vanilloids and endovanilloids on platelets.  
Vanilloids 0μM 25μM 100μM 
CAP 0% 0% 0% 
DHC 0% 0% 0% 
NADA 0% 0% 0% 
OLDA 0% 0% 0% 
Data are presented as percent (%) of cytotoxicity of 4 experiments for 
capsaicin (CAP), dihydrocapsaicin (DHC), N-arachidonoyl-dopamine 
(NADA) and N-oleoyldopamine (OLDA). Data are the percent of triplicate 
absorbance value – low control, divided by high control – low control.   
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3.6 Effect of Vanilloids on Alpha Granule Release  
Capsaicin, DHC and OLDA inhibited the release of PF4 in a concentration-
dependent manner by 5 and 10M ADP.   NADA (3.125 and 25 M) enhanced PF4 
release, whereas 100 M NADA inhibited PF4 release (Figure 3.13 C,D).  
 
In the presence of 5M ADP, all vanilloids increased β-TG release, while at 10M 
ADP, only DHC and NADA increased release. However, capsaicin inhibited β-TG 
release in a concentration-dependent manner.  β-TG release was inhibited by 3.125 
and 25M OLDA inhibited at then evoked at 100M. These results are for two 
samples only and need to be validated (Figure 3.13 A,B). 
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Platelets play an important role in thrombogenesis, with antiplatelet medications 
such as the cyclooxygenase inhibitors, the most effective drugs for the treatment and 
prevention of atherothromobotic diseases (Patrono et al., 2004). These drugs 
however, have a number of side effects such as gastrointestinal bleeding and urticaria 
(Group, 1991, Mastalerz et al., 2004). Naturally occurring antiplatelet compounds 
potentially exhibit fewer adverse effects than existing medications and may be useful 
as adjuvant or alternative to conventional antiplatelet medications. Capsaicin, the 
plant derived vanilloid, exerts its action through transient receptor potential vanilloid 
1 (TRPV1) and TRPV1-independent mechanisms (Caterina and Julius, 2001). Along 
with other endogenous and exogenous vanilloid-like agents, capsaicin has been 
suggested to contain antiplatelet activity. However, the precise mechanism(s) of 
capsaicin action on platelets remain poorly understood. In this study the effects of 
plant-derived vanilloids; capsaicin and DHC, and endogenous vanilloids; OLDA and 
NADA on in vitro human platelet aggregation and their potential mechanism of 
action, have been investigated. 
  
To the best of our knowledge, this is the first study to systematically investigate the 
effects of plant-derived (capsaicin and DHC) and endogenous vanilloids (OLDA and 
NADA) on platelet aggregation using an array of platelet agonists; ADP, collagen 
and AA. Furthermore, the potentially direct toxic effects of these compounds on 
platelets, and the impact on platelet function via alpha granule release, were 
investigated.  
 
Capsaicin, OLDA and NADA significantly inhibited platelet aggregation induced by 
ADP in a concentration-dependent manner, while DHC had negligible effect on 
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ADP-induced aggregation. Interestingly, two previous studies have shown the same 
effect of capsaicin on in vitro human platelet aggregation induced by ADP (Adams et 
al., 2009, Raghavendra and Naidu, 2009).  Although Adams et al. used the same in 
vitro aggregometery technique that has been used in the current study, they instead 
demonstrated that DHC enhanced the aggregation at low concentrations and 
inhibited at higher concentrations. The cause(s) for this is unknown but it might be 
due to different normal variation of the platelets donors.    
 
Recently, it has reported that aggregation of canine platelets induced by collagen was 
completely inhibited by capsaicin (Mittelstadt et al., 2012). Furthermore, the same 
type of effect was demonstrated using human platelets (Raghavendra and Naidu, 
2009). These finding are in contrast to those in the present study, where neither 
capsaicin nor DHC had any effect on the aggregation of human platelets induced by 
either 4 or 8µg/mL collagen.  Moreover, the current study has demonstrated that the 
endovanilloids, OLDA and NADA, significantly inhibited platelet aggregation 
induced by 4g/mL but not 8g/mL collagen in a concentration-dependent manner.  
The reasons for the discrepant results across these studies are not known, however it 
may be due to the use of washed human platelets that were pre-incubated with 
capsaicin for five minutes prior to the addition of collagen (Raghavendra and Naidu, 
2009) or species differences between the platelets from human compared to canine 
(Mittelstadt et al., 2012). 
 
Capsaicin, DHC and NADA significantly inhibited the aggregation induced by 300 
and 400 mg/mL AA and was concentration-dependent. The most potent vanilloid 
was capsaicin that inhibited the aggregation at 100µM by 90% followed by 50% 
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inhibition by 50µM. A similar effect of 60µM capsaicin has been reported on platelet 
aggregation induced by AA (Raghavendra and Naidu, 2009). As stated earlier it is 
not known why there are differences between the studies, but it might be due to the 
use of washed human platelets and/or pre-incubution with capsaicin for five minutes 
prior to the addition of AA. Nevertheless, capsicin seems to interfere with the AA 
pathway.   
 
The effects of capsaicin, DHC and other vanilloid-like agents on neuronal cells are 
mediated by both TRPV1-dependent and independent mechanisms (Caterina and 
Julius, 2001).  To determine the contribution of TRPV1 activation toward the 
inhibitory effects of vanilloids on ADP-induced platelet aggregation, experiments 
were conducted in the presence of SB452533, a potent and selective TRPV1 
antagonist.  The inhibitory effects of capsaicin and OLDA on ADP-induced 
aggregation were not affected by SB452533, suggesting that the effects of these 
vanilloids were independent of TRPV1 activation. Although the present results are 
similar to those of a recent study that investigated the effect of TRPV1 antagonist 
(A-993610) on capsaicin’s inhibition of collagen-induced aggregation of canine 
platelets (Mittelstadt et al., 2012), this does not exclude a role for CB receptors in the 
actions of either capsaicin or OLDA.  The role of CB receptors in the inhibition of 
platelet aggregation remains to be investigated. 
 
Vanilloids have been shown in many previous studies to be cytotoxic, particularly at 
higher concentrations, e.g., >25µM. In our laboratory for example, it has reported 
that 100µM NADA resulted in 100 percent cell death of human peripheral blood 
mononuclear cells (Saunders et al., 2009).  Hence, to determine whether the 
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inhibition of platelet aggregation might be due to the direct platelet destruction by 
vanilloids, platelet LHD release following exposure to ADP, in the absence and 
presence of vanilloids, was measured. In the present study, four separate experiments 
were designed using three controls; background control (assay media), low control 
(cells only) and high control (100% cells lysis). The LDH level of vanilloids treated 
cells were the same as low control.  None of the vanilloids tested (at up to 100 M) 
had any effect on LDH release.  Hence, the inhibitory effects of vanilloids were not 
due to direct cytotoxicity.   
 
Following confirmation that the vanilloid-like agents were not cytotoxic toward 
platelets, we investigated their effect on alpha granule release from platelets. Platelet 
alpha granules contain numerous haemostatic and non-haemostatic components (see 
chapter 1) that play a very important role in their function. PF4 and -TG are 
synthesized only in megakaryocytes, and are secreted via exocytosis after platelet 
activation by strong and/or by weak agonists through TxA2 generation. Protein 
kinase C, intracellular Ca+2 and other factors regulate the fusion of alpha granule 
vesicles to the membrane (Reed, 2004, Reed et al., 2000). -TG enhances neutrophil 
chemotaxis and adherence to endothelial cells (Brandt et al., 2000) and PF4 act as 
anticoagulant by binding to heparin with high affinity (Gupta and Singh, 1994). 
Accordingly, the effects of capsaicin, DHC, NADA and OLDA along with 10M or 
5M ADP, on PF4 and -TG release, were investigated.  It was demonstrated that all 
vanilloids, with the exception of NADA, decreased the PF4 release and only 
capsaicin and OLDA decreased -TG release.  
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It is important to note that the data presented has been generated by only two 
separate experiments, so this clearly needs to be further validated. However, it would 
appear that the preliminary data suggests that alpha granule release is affected by 
some vanilloids, especially OLDA and capsaicin. In comparison to the aggregation 
results, OLDA showed a strong effect on platelet aggregation induced by ADP and 
capsaicin too but to lesser extend comparing to OLDA. These effects might be 
through blocking of one and/or all ADP receptors directly, or by interfering with the 
intracellular signaling that leads to platelet secretion.  
 
The precise mechanism/s of action of endogenous and plant-derived vanilloids on 
platelet aggregation remain to be elucidated, although numerous hypotheses have 
been proposed. A previous study showed that TRPV1 is present in platelets, and that 
capsaicin enhanced platelet aggregation in the absence of ADP or other platelet 
agonists, by increasing intracellular Ca+2 (Harper et al., 2009).  Others have found 
that capsaicin rather inhibits cyclooxygenase1 (COX1), which may therefore result 
in a dampening of platelet aggregation (Raghavendra and Naidu, 2009). 
Furthermore, it has been suggested that capsaicin inhibits aggregation by inserting 
into platelet plasma membranes, changing its permeability and fluidity (Hogaboam 
and Wallace, 1991). A recent study has shown that capsaicin inhibited the 
aggregation of platelets and that it was not TRPV1 mediated (Mittelstadt et al., 
2012). The results of the current study, using both endogenous and plant-derived 
vanilloids, strongly suggest that the inhibition of aggregation is not TRPV1 
mediated, in agreement with these previous studies. The reason(s) for the 
contradictory results, i.e., activation vs inhibition, is unknown, however there are 
different possibilities. First, these studies used different techniques and platelets 
	 75
preparation. Second, they used variant types of agonists and concentrations, also 
different concentrations of capsaicin and incubation times. Finally, it may be due to 
use of different platelet species and various volunteer criteria. 
 
It was demonstrated that each vanilloid and endovanilloid/endocannabinoid produced 
different effects on platelet aggregation, depending on the agonist employed. These 
agonist-related differences may be due to different mechanisms of action and the 
different respective pathways of action. Collagen enhances cytosolic Ca2+ by binding 
directly to α2β1 and GPVI, and indirectly through vWF αIIbβ3 and GPIb-IX-V, which 
activate granule release (ADP and serotonin) (Massberg et al., 2003, Kato et al., 
2003). ADP instead binds to G-coupled protein receptors causing shape change, 
secretion, TxA2 formation and aggregation, and also increases intracellular Ca2+ via 
the activation of PLC (Jin et al., 1998). AA is converted to TxA2 via a series 
enzymatic reaction including COX1, increasing intracellular Ca2+ through activation 
of PLC (Nesbitt et al., 2003). Considering these pathways, it is interesting to 
speculate how the vanilloids investigated in this study interfere with platelets.  
 
NADA was the only vanilloid to inhibit aggregation induced by all three agonists, 
and to the same degree. This effect might be through either direct blocking of CB1 
and/or CB2 receptors, or non-specifically decreasing intracellular Ca2+, or through 
unknown receptor/s.  However, the effect of NADA as an endocannabinoid are 
opposite to those of Delta-9-tetrahydrocannabinol (THC), which activates human 
platelets by increasing P selectin and GPIIb/IIIa expression (Deusch et al., 2004). 
Furthermore, it increases 2-arachidonylglycerol (2-AG) levels, resulting in activation 
of platelets through the AA pathway (Nakahata, 2008). A further study has shown 
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that anandamide activates rabbit platelets through the same pathway (Braud et al., 
2000). The previous studies showed that it is not CB1 or CB2 mediated. On the other 
hand, it has been reported that anandamide (arachidonoylethanlamide, AnNH) 
activates human platelets through a mechanism independent of the AA pathway 
(Maccarrone et al., 1999). Later, the same group has shown that 2-AG mediated 
aggregation via an uncharacterized CB receptor (MacCarrone et al., 2001). The 
cause(s) for the conflicting results are uncertain, but it may be because each 
cannabinoid behaved differently. Moreover, these studies generated their results 
using different techniques, cannabinoids concentrations and incubation times. 
  
The results of the current study suggest that OLDA may act through the blocking of 
the ADP receptors, P2Y1 and/or P2Y12, or by interfering/blocking of the 
intracellular ADP signaling pathway, as complete inhibition of aggregation induced 
by ADP was demonstrated. OLDA also damped aggregation mediated by collagen, 
with this effect completely inhibited by higher concentrations of collagen. This 
suggests that OLDA may be exerting its action through a non-receptor pathway, i.e., 
inserting directly into the phospholipid bilayer, or by partially antagonizing one or 
more collagen receptors. Although this inhibition was not through TRPV1, CB 
receptors and/or unknown receptors may be involved. Capsaicin and DHC 
completely inhibited aggregation induced by AA, which may be through the 
inhibition of COX1, in agreement with the previous study of (Raghavendra and 
Naidu, 2009). In addition, capsaicin also damped aggregation meditated by ADP, 
which may be due to partially antagonizing an ADP receptor or by impeding the 
intracellular signaling as capsaicin decreased alpha granule secretion. Moreover, the 
role of TRPV1 in capsaicin action has been excluded according to the results. The 
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nature of vanilloids and endovanilloids/endocannabinoids targets and actions on 
platelet remain to be elucidated. 
 
Although this study has achieved most of its initial aims, there are number of 
limitations primarily due to time constraints. Firstly, the effects of vanilloids and 
endovanilloids/endocannabinoids on dense granule release, e.g., serotonin, were not 
completed. Secondly, the effects of TRPV1 antagonists with NADA, and the effects 
of CB1 and CB2 antagonists with vanilloids, on platelet aggregation, were also not 
investigated. Finally, alpha granule (PF4 and -TG) data presented in this study is 
from only two experiments, and thus clearly needs to be confirmed.  
 
Future directions include studies using whole blood aggregometry to determine the 
effects of endovanilloids/endocannabinoids on platelet aggregation, which more 
closely mimic in vivo conditions. Moreover, it would be useful to examine the 
effectiveness of endovanilloids/endocannabinoids in platelet hyperactivity disorders, 
such as the antiphospholipid syndrome, sticky platelet syndrome, myeloproliferative 
disorders, and others. Finally, the potential mechanism of action of 
endovanilloids/endocannabinoids, especially NADA, on platelet aggregation 
warrants further investigation. In this regard, Ca2+ flux studies, such as those 
performed by (Harper et al., 2009), would be useful. 
 
In conclusion, the current study showed that exposure of platelets to capsaicin, DHC, 
NADA and OLDA inhibited platelet aggregation induced by ADP, collagen and AA 
albeit to different degrees. Additionally, the inhibitory effects of the vanilloids were 
not shown to be due to platelets destruction nor mediated by TRPV1 activation. In 
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addition, we found that vanilloids and endovanilloid might affect alpha granule 
secretion. The latter finding should be investigated further to find out at which 
cellular level this effect is occurring. Vanilloids and 
endovanilloids/endocannabinoids have potent antiplatelet activity and should be 
further investigated as potential antiplatelet and/or adjuvant with antiplatelet 
medications.  
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